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Chapter 1.  Introduction 
10
Chronic wasting disease (CWD) is a transmissible spongiform encephalopathy 
that affects cervid species (deer, elk, and moose) in both captive and wild animals.  Since 
first identified and described in the late 1970’s, CWD has had significant impact upon the 
captive cervid industry and has been found in an increasingly large geographic area of 
North America in wild populations.  The association of bovine spongiform 
encephalopathy (a similar disease that occurs in cattle) with a new form of human 
encephalopathy in 1986 caused a dramatic increase in awareness and concern about all 
transmissible encephalopathies, including CWD.  This led to an increase in surveillance 
efforts for CWD that may account for part of the expanding incidence that has been 
reported in the last twenty years.  Although there are no reports of zoonotic disease 
associated with CWD and there are lines of evidence that show transmission to humans is 
unlikely, the infectious agent has recently been identified in skeletal muscle of mule deer 
and the exact nature of the infectious agent is still poorly understood.   
One of the most complex problems associated with CWD and other transmissible 
spongiform encephalopathies is the lack of diagnostic methods to identify preclinical 
cases of disease.  The studies described herein are focused on solving this difficult 
problem using some novel approaches as compared to development of diagnostic 
strategies for other infectious agents.  The first study is a discovery based experiment 
designed to select a nucleic acid recognition ligand, and the second is designed to 
develop a model of CWD in cell culture that could serve as a very sensitive detection 
system. 
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Both of these studies were high risk endeavors attempting to solve the diagnostic 
dilemma of prion diseases with some very novel approaches.  The identification of one 
aptamer that shows some specificity for PrPCWD only opens the door for further 
characterization and adaptation of this potential ligand. The results of the cell culture 
model development raise some stimulation questions about prion protein trafficking and 
control, and served as a basis for the development of other cell culture models.  
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Chapter 2.  Literature Review 
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Abstract 
Chronic Wasting Disease (CWD), an emerging infectious disease that affects cervid 
species in North America, is a transmissible spongiform encephalopathy (TSE), or prion 
disease caused by a unique transmissible agent hypothesized to be a misfolded form 
(PrPCWD) of a normal host protein (PrPC). This misfolding occurs via direct protein-
protein interaction of PrPC with PrPCWD resulting in aggregation and accumulation of 
PrPCWD in CNS.  CWD first occurred in 1967 in captive deer in Colorado and Wyoming 
and has been described in an increasingly large geographic area since, due to either a 
spreading epidemic, improved surveillance, or both.  Natural transmission via 
environmental contamination with PrPCWD has been shown to occur and impacts control 
and eradication efforts.  Pathogenesis includes ingestion of the agent, replication and 
amplification in lymphoid tissue, transfer to neurons, and spread to the CNS.  The course 
of disease is prolonged and uniformly fatal.  Diagnosis of prion disease presents a unique 
challenge because animals are immunotolerant to PrP, few monoclonal antibodies have 
been developed that reportedly distinguish PrPCWD from PrPC, and none have been 
adapted for use in a diagnostic setting.  Most diagnostic assays rely upon use of 
monoclonal antibodies that recognize both isoforms of PrP following the removal of PrPC
from the sample by treatment with proteinase K leaving the more proteinase K-resistant 
PrPCWD. This review summarizes the current understanding of the pathogenesis and 
diagnosis of CWD.  Review of other prion diseases is included as necessary to highlight 
important areas of molecular and cellular pathogenesis. 
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Introduction 
Chronic Wasting Disease (CWD) is a transmissible spongiform encephalopathy 
(TSE) that affects mule deer (Odocoileus hemionus hemionus), Rocky Mountain elk 
(Cervis elaphus nelsoni), white tailed deer (Odocoileus virginianus), and moose (Alces 
alces) in North America.  Other TSEs include Kuru, Creutzfeld Jakob’s disease (CJD) 
and variant Creutzfeld Jakob’s disease (vCJD) of humans; bovine spongiform 
encephalopathy (BSE) of cattle; scrapie of sheep; and transmissible mink encephalopathy 
(TME).  These diseases are also called prion diseases because they are thought to be 
caused by a unique transmissible agent termed a prion.  The diseases caused by prions are 
unique in that they occur (at least in humans) in infectious, sporadic, and genetic forms.  
The name prion was coined by Dr. Stanley Prusiner to describe what he and his co-
workers were observing in their experiments using scrapie.  Expanding on the pioneering 
work by Gadjusek, Gibbs, Hadlow and others who made the connection between scrapie, 
Kuru, and CJD as infectious diseases [1, 2], Prusiner and associates began trying to 
isolate and characterize the infectious agent using scrapie passed into mice as a model.  In 
the course of these experiments, they noted several unique properties, including 
sensitivity to proteases and resistance to most reagents which inactivate nucleic acids  [3-
7].  These properties led to the definition of a prion as “a small proteinaceous infectious 
particle which is resistant to inactivation by most procedures that modify nucleic acids” 
[8].  While extremely controversial at the time and still not fully accepted by all 
investigators, the prion hypothesis continues to provide a plausible explanation for the 
infectious agent of TSE’s and has assisted in our understanding of these diseases over the 
last twenty-two years.  The primary alternative hypothesis is that these diseases are 
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caused by an uncharacterized virus, but the lack of supporting evidence in the face of 
many studies looking for such a virus makes this theory less likely [9].  Additionally, two 
recent studies have provided the strongest support to date for the prion hypothesis.  In one 
of these studies, Legname et al. used a recombinant PrP folded in vitro to a high β-sheet 
content to induce disease in transgenic mice that expressed high levels of PrP [10].  In the 
other study, Castilla et al. generated infectious prions in vitro by a cyclic process termed 
protein misfolding by cyclic amplification (PMCA) [11].  These two lines of evidence 
have not been totally accepted as proof of the prion hypothesis because the mice in the 
first study have been shown to spontaneously develop prion disease and the source 
material for PMCA in the Castilla study was normal hamster brain, and therefore 
contained molecules other than prion protein.  The emergence of BSE in 1986 [12] and 
its subsequent link to variant CJD (vCJD) [13] led to enormous public interest in prion 
diseases, a dramatic increase in research, and subsequent escalation in publications in the 
scientific literature. 
This review will focus on the literature describing the pathobiology and 
diagnostic issues primarily relating to CWD by means of the prion paradigm.  Review of 
other prion diseases will be included as necessary to highlight important areas of 
difference and in the areas of molecular and cellular pathogenesis as most modeling 
studies for TSEs utilize prion strains adapted into laboratory animals.  The abbreviation 
PrPC is used to indicate normal cellular prion protein; PrPSC is used to describe the 
misfolded prion protein in general discussions of prion diseases; PrPCWD is used to 
indicate the disease associated, misfolded prion protein associated with chronic wasting 




Gene structure and organization of Prnp 
 The gene encoding PrP is one of two known members of the Prn gene family.  
The other, Prnd, lies approximately 19 kb downstream of Prnp and encodes the doppel 
(Dpl) protein [14].  These two genes represent an ancient duplication event; the proteins 
encoded by them show only about 25% sequence homology but their structures have 
retained remarkable similarity; their functions have apparently diverged with their 
sequences [15].  The open reading frame of all mammalian PrP genes lies within a single 
exon [16, 17].  There is conservation of sequence across different classes of animals 
including amphibians [18], reptiles [19], avians and mammals [20] that is strong 
evolutionary evidence for important function of the translated protein.  The functional 
mule deer gene is 19.9 kb in length and contains three exons similar to that of bovine, 
ovine, human and murine Prnp (figure 2-1) [21]. Brayton et al. reported lengths of 
exons 1, 2, and 3 respectively are 54, 98, and 4083 nucleotides separated by introns of 
2407 and 13,252 nucleotides.  The PrP open reading frame lies entirely within exon 3. 
The 3' untranslated region of exon 3 contains a mariner transposon that is also 
found in the ovine and bovine Prnp and predicted to be present in all ruminants [17].  
Mariner transposons are mobile genetic elements classified as DNA transposons that 
generally are excised from one area of the genome and placed in another rather than 
being copied and pasted as with retroviral transposons [22].  Lee et al. described the 
mariner transposon identified in sheep as a relic because it is actually a pseudogene 
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containing multiple frame shifts and stop mutations.  The deduced amino acid sequence 
of the transposase placed this transposon in the Mellifera (honeybee) subfamily.   
Mule deer and white-tailed deer, but not elk, have a processed pseudogene 
(ΨPrnp), a non-functional retrotransposable element having characteristics of a copy of 
mRNA [21, 23].  These characteristics are present in ΨPrnp and include the lack of 
introns and a 5' promoter sequence but the presence of a poly(A) tract and flanking direct 
repeats.  Brayton et al. reported that no detectable mRNA was present in a preparation of 
cDNA from mule deer peripheral leukocytes indicating that ΨPrnp is not transcribed.  
They went on to describe in detail one clone of the mule deer ΨPrnp as 4223 bp in length 
with truncation of bp 1-25 from exon 1, containing 33bp substitutions with six of these in 
the coding region, and three insertions and three deletions relative to the functional gene 
(all within the 3’ untranslated region).  The presence of the pseudogene has caused some 
confounding results in attempts to characterize the sequence Prnp (see discussion of 
polymorphisms below) from these species.    
 Prnp promoter regions have been identified in the 5' untranslated of region of 
exon 1 for many species, including deer and elk [24-29].  A study of bovine Prnp 
identified a G-C rich region from the transcription start position to nucleotide -88 that 
contained three potential binding sites for the transcription factor SP1 at positions -6 to -
11, -22 to -27, and -42 to -47 [26].  This transcription factor has been shown to have 
activity in many genes [30] and may indicate that Prnp is constitutively transcribed.  
Inoue et al. reported that the region from -30 to -88 showed strong promoter activity, but 
no TATA box or CCAAT box was identified and promoter activity only functioned 
properly in conjunction with the region at position +123 to +891 of intron 1.  The region 
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analyzed showed high homology with that of sheep Prnp. Although cervid and ovine 
Prnp show generally high sequence homology, Heaton et al. have reported much greater 
variation in the 5' untranslated region of the deer PrP gene [24] such that the promoter 
activity identified in bovine Prnp may not apply to the cervid gene. 
 
Prion protein structure 
 PrPC is a normal, constitutively expressed protein present in most cells but 
expressed at higher levels in neuronal and lymphoid cells [31].  PrPSC differs from PrPC
in the secondary and tertiary structure of the protein [32].  Thus an understanding of the 
basic structure of PrPC is vital to studies of prion disease.  The ORF for cervid PrPC
encodes a peptide of 256 amino acids.  The major features of this peptide include (see 
figure 2-2): 
• a twenty-four amino acid N-terminal signal peptide 
• five octapeptide repeats (PHGGGWGQ) in the region spanning residues 54 – 95 
• N-linked glycosylation sites at residues residues 189 and 205 
• di-sulfide bridge between cysteine residues 187 and 222  
• glycophosphatidylinositol (GPI) anchor signal sequence comprised of the C-
terminal 23 amino acids 
PrP is synthesized by membrane bound ribosomes, and the amino terminal signal 
peptide is responsible for directing it into the endoplasmic reticulum concurrent with 
synthesis [33].  The signal peptide is cleaved as the peptide is directed into the rough 
endoplasmic reticulum, where asparagine-linked (N-linked) oligosaccharide chains are 
added at residues 189 and 205.  These N-linked oligosaccharide chains are added initially 
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in the endoplasmic reticulum where they are of the high-mannose type glycans and are 
sensitive to digestion with endoglycosidase H.  The high-mannose glycans are 
subsequently modified in the Golgi, yielding more complex-type chains that contain 
sialic acid and are resistant to endoglycosidase H.  These glycans are composed of at least 
52 different bi-, tri, and tetra-antennary structures and are large enough to shield 
complete faces of the three dimensional protein structure and confer some degree of 
stability to PrPC [34-36].  Glycosylation patterns of PrP can be detected on SDS-PAGE 
gels due to the ‘ladder’ effect reflected in a typical banding pattern for unglycosylated, 
mono-glycosylated, and di-glycosylated PrP.  These glycosylation patterns have been 
suggested as one way to differentiate different ‘strains’ of PrPSC [37].  It has also been 
suggested that alternative topologies and tethering patterns of the prion glycoprotein on 
the cell surface can affect glycan site occupancy and may play a role in prion disease 
pathogenesis [35].  Although no differences were noted in the biosynthesis of PrP, 
including it’s glycosylation, in scrapie infected versus uninfected neuroblastoma cells 
[38], other studies in mice have suggested that TSE agents affect glycosylation during 
PrP biosynthesis [39, 40].  Race et al. compared the glycosylation patterns in CWD 
affected deer, elk, sheep, and cattle and noted differences within individuals of the same 
species but similarities of CWD to scrapie [41].  The glycosylation pattern of elk PrPCWD 
tended to have less variability leading the authors to postulate that perhaps elk were 
infected with one strain whereas the other species were infected with multiple strains.  
The degree of glycosylation and pattern noted on SDS-PAGE gels for a particular prion 
strain results from an interplay of the agent, the genotype of the host, and the cellular 
source of PrPSC [40].  
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Other post translational events that occur in the endoplasmic reticulum are the 
addition of a single disulfide bond between cysteine residues 187 and 222, and the 
replacement of the GPI anchor signal sequence by the GPI anchor.  GPI anchored 
proteins are a very diverse group and are present on the cell membranes of virtually all 
mammalian cell types [42].  GPI anchors all share a core structure of a phosphatidyl 
inositol that is linked via a glycosidic bond to a non-acetylated glucosamine that is in turn 
glycosidically linked to a series of three mannose residues.  These mannose residues are 
linked to a phosphoethanolamine through a phosphodiester bond, and the terminal amine 
group of the phosphatidylethanolamine is linked to the carboxy end of the peptide via an 
amide bond [43].  Heterogeneity of GPI anchors occurs through the addition of other 
modifying groups to the fatty acid chain or through side chain modifications of the 
tetrasaccharide core.  The prion protein has been shown to have mannose, ethanolamine, 
and sialic acid residues added to its GPI anchor [44].  GPI anchors are preassembled on 
the cytosolic surface of the endoplasmic reticulum before their addition to proteins.  
Attachment of the GPI anchor to the peptide is a posttranslational event that involves a 
transamidation reaction resulting in cleavage of the carboxy terminal GPI signal sequence 
from the peptide and en bloc transfer of the preassembled GPI anchor inside the 
endoplasmic reticulum [43].    
The GPI anchor acts to localize associated proteins to lipid rafts on the plasma 
membrane [43].  GPI anchored proteins lack a transmembrane domain and yet some 
authors have postulated that they can act as signal transducers either through release of 
GPI anchor degradation products into the cytosol or through a poorly understood 
mechanism associated with tyrosine kinase [45].  The lack of transmembrane domains 
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may allow more freedom of movement on the cell surface and allow GPI anchored 
proteins to more easily interact with ligands.  GPI anchored proteins can be released from 
the cell surface with phosphatidylinositol-specific phospholipase C (PIPLC) which 
specifically cleaves the GPI anchor, a property which has been used to release PrPC from 
in vitro cell cultures [46].  Finally, GPI-anchored proteins may play a role in potocytosis 
[47], a cellular process to take up small molecules in calveolae without locating them to 
internal endosomal/lysosomal compartments as occurs in endocytosis.  These GPI-
anchored proteins, which include the prion protein, are associated with calveolae.  In 
general, small molecules can be captured and taken into the cell against their 
concentration gradient where they are released enzymatically or through a change in pH.  
The molecules can then transit out of the calveolae by diffusion, and the calveolae re-
open on the cell surface.   
The five octapeptide repeats found in cervid PrP are actually three octapeptides and 
two nonapeptides.  The first in this series (from amino acid residue 52-60) is the 
nonapeptide PQGGGGWGQ.  This is followed by three repeats of the octapeptide 
PHGGGWGQ.  The sequence of the human and sheep protein is the same in this region, 
but the cow prion protein contains one extra insert of the octapeptide between the first 
and second octapeptide of the elk, human and sheep sequence.  The last peptide repeat 
contains an inserted glycine in the cow, sheep, and elk and reads PHGGGGWGQ [48].   
This series of repeated peptides is highly conserved between species, which implies a 
functionally important role.  Insertions of extra repeats in this region have been 
associated with familial CJD (fCJD) [49, 50], but deletions of single octarepeats do not 
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appear to cause disease, and PrPC with complete deletion of the octapeptide repeats can 
still be converted to PrPSC [51, 52]. 
One role postulated for the function of PrPC is in the regulation of intracellular 
copper, and the repeated histidine residues in the octapeptide repeat region have been 
proposed as a metal binding site.  Some investigators have taken advantage of this idea to 
purify prion proteins by metal ion affinity chromatography [53]  using immobilized Cu++.
Several other investigators have shown that PrP binds to copper [54-56], and others have 
shown that PrP specifically binds Cu++ with higher affinity than other metal ions [57].  
Further evidence that PrP plays a regulatory role in copper homeostasis comes from 
studies using recombinant PrP that show that histidine residues in the octarepeat region 
are oxidized by Cu++ [58].  Additionally, mice with homozygous knockout of Prnp 
(Prnp0/0 or PrP null mice) have been shown to have reduced levels of Cu++ and reduced 
activity of Cu-Zn superoxide dismutase as compared to wild type mice [59].  A proposed 
model for PrP regulation  of copper involves the release of PrP from neurons where it 
binds and collects Cu++, and the PrP-Cu++ complex is specifically taken up by astrocytes 
[60].  This model explains the neuroprotective effect by PrP on neurons [61].  The exact 
role of PrP in regulation of copper and protection of cells from oxidative stress has yet to 
be elucidated, but these experiments provide evidence to support this general hypothesis 
and the affinity of the octarepeat region for Cu++ indicates that this region may play a 
crucial role in this function. 
Immediately following the conserved octarepeat is another highly conserved alanine-
glycine region spanning residues 115-130 of the elk prion protein.  This region has been 
proposed as the potential site of interaction between PrP molecules during crucial early 
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steps of the conversion of PrPC to PrPSC [62].  Evidence to support this came from 
experiments using peptides spanning this region that were able to block conversion of 
PrPC to PrPSC in a cell free conversion assay.  This region also contains a known point 
mutation from alanine 117 (119 in elk) to valine that is linked to Gerstmann-Straussler-
Scheinker syndrome in humans [63].  
Secondary structure of the prion protein is one of the known differences between 
PrPC and PrPSC. Fourier-transform infrared spectroscopy and circular dichroism studies 
performed comparing the secondary structure of PrPC and PrPSC purified from Syrian 
hamster brains have shown that PrPC contains 42% α-helix and has little β-sheet (3%), 
whereas PrPSC has 30%  α-helix and 43% β-sheet content [64].  The structure of 
recombinant PrP (thought to represent PrPC) has been solved by NMR and has been 
shown to contain three α-helices as noted in figure 2-2 [65-67].  This α to β conversion is 
a fundamental event underlying the conversion of PrPC to PrPSC [48].  The exact three 
dimensional structure of PrPSC has not been solved due to difficulty purifying and 
crystallizing the misfolded protein. 
 
Cellular trafficking of prion protein 
 After PrPC has been produced and attached to the cell surface by its GPI anchor, it 
does not remain statically there; it has been shown to constituitively cycle between the 
plasma membrane and an endocytic environment [68].  Evidence supporting this 
understanding is the finding that PrPC undergoes physiologic cleavage near human 
residue 110 (112 elk) [69, 70], carried out by disintegrins [71] and this can be inhibited 
with the lysosomal protease inhibitors leupeptin and brefeldin [68], consistent with this 
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step occurring within an endocytic compartment.  Other data from these experiments 
indicate that PrPC cycles through the cell with a transit time of approximately 60 minutes 
and that during each passage approximately 1-5% of the PrPC molecules undergo 
cleavage near residue 110. 
 The mechanism by which PrPC undergoes endocytosis is not completely clear.  
Some investigators have shown that PrPC is associated with clathrin coated pits [72, 73], 
but the lack of a transmembrane domain makes if difficult to understand how it associates 
with clathrin or adapter proteins inside the cell.  As mentioned above, many GPI 
anchored proteins are associated with caveolae or caveolae-like domains (CLDs) which 
are rich in cholesterol and are specialized membrane microdomains and often appear as 
flask-shaped invaginations on the plasma membrane.  PrPC has been demonstrated in 
both CLDs and CLD-containing endocytic structures of cell culture models [74].  CLDs 
appear to be an important site, if not the site, of the conversion of PrPC to PrPSC as 
evidenced by the inhibition of conversion by depletion of cholesterol from a cell culture 
model [75] and inhibition by redirecting the protein to clathrin coated pits via the use of a 
modified carboxy-terminal signal peptide [76].   
 Thus the cellular trafficking of PrPC involves a constituitive cycling from the cell 
membrane, probably in CLDs, to an endocytic compartment where a small percentage of 
it undergoes a physiologic cleavage near residue 110 and the majority is returned to the 
cell membrane.  Important processes involved in the the conversion of PrPC to PrPSC are 
thought to occur inside this endocytic compartment,.  Conversion in this endocytic 
compartment may be enhanced due to changes in pH and/or exposure of native PrPC to 
25
very high concentrations of PrPSC or other auxiliary molecules in this compartment [77, 
78]. 
 
History of Chronic Wasting Disease 
About the same time that researchers were beginning to understand that transmissible 
spongiform encephalopathies were novel infectious diseases, Dr. Elizabeth Williams and 
co-workers at Colorado State University published the first scientific description of CWD 
in mule deer [79].  The disease had been occurring in captive mule deer held in several 
wildlife facilities since 1967, but was not recognized as a spongiform encephalopathy 
until Dr. Williams’ description.  The disease was subsequently identified in Rocky 
Mountain elk and mule deer/white-tailed deer hybrids housed at the same wildlife 
research facilities [80].  New cases of the disease in free ranging species then began to be 
diagnosed in the same geographic area (northeastern Colorado and southeastern 
Wyoming, USA) where the captive animals diagnosed with the disease were held [81, 
82].  CWD was first identified in farmed elk in 1996, but was apparently present in the 
North American elk industry before that [83] and Williams described cases in two 
zoological collections in the early 1970s and 1980s [84].  After the first reports in elk, 
CWD was subsequently identified on many elk farms throughout North America and  in 
South Korean elk imported from Canada [85, 86].   With reports and descriptions of 
CWD occurring at the height of BSE awareness, many states instituted surveillance and 
monitoring programs coinciding with the deer and elk harvests and the United States 
Department of Agriculture (USDA) began active surveillance of captive cervids.  The 
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incidence of CWD is occurring in an increasingly large geographic area either as the 






Documented cases of natural transmission of CWD are limited to four species, all 
of which are members of the family Cervidae:  mule deer (Odocoileus hemionus 
hemionus), white-tailed deer (Odocoileus virginianus), Rocky Mountain elk (Cervis 
elaphus nelsoni), and moose (Alces alces) [87-89].  CWD is an efficiently transmitted 
prion disease in a susceptible population, with incidence rates in susceptible animals held 
in a captive herd for two years or more approaching 90%  [79] and prevalence in wild 
animals  up to 15% in endemic areas [90].  In contrast to BSE, TME, Kuru, and vCJD 
that require ingestion of the agent in feed, CWD and scrapie have been shown to be 
transmited naturally from animal to animal and/or acquired from contaminated 
environments [91-93].    
Epidemiologic evidence originally identified a maternal or horizontal route of 
transmission [94].  Subsequent epidemiologic investigations showed that the role of 
maternal transmission was probably very small compared to the horizontal route [95] and 
a descriptive pathologic study comparing CWD in wild and free ranging mule deer 
reported no histologic lesions or IHC staining in any of the reproductive tissues examined 
[96].  However, these authors only reported examining one pregnant doe in their study, 
and Tuo et al. have reported that uterine and placental accumulation of PrPSC in scrapie 
infected ewes is dependent upon the pregnancy status of the ewe and the presence of a 
susceptible fetal genotype [97].  Therefore, the absence of PrPCWD in an unspecified 
number of female reproductive tracts and one pregnant female in the study by Spraker et 
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al. [96] does not preclude a maternal route of transmission or environmental 
contamination by placental and uterine tissues as seen with scrapie.   
Studies showing the early accumulation of PrPCWD in the lymphoid tissues of the 
alimentary tract after oral inoculation of mule deer fawns with mule deer brain 
homogenates prepared from naturally occurring cases of CWD led to the hypothesis that 
naturally occurring CWD could be shed in feces or saliva and spread to susceptible 
animals via the oral route [98].  Miller et al. showed that transmission of CWD could 
occur by both direct lateral transmission and by indirect contamination of pastures [91].  
This indirect transmission occurred in both pastures where infected deer had resided over 
2.2 years prior to re-introduction of susceptible animals and in pastures contaminated 
with the decomposing deer carcasses over 1.8 years prior to re-introduction of susceptible 
animals.  A recent study identified infectious prions in the saliva from CWD positive 
mule deer that caused disease in white-tailed deer fawns exposed orally and in blood 
from the mule deer given intravenously and intraperitoneally [99].  The indirect 
transmission by environmental contamination, the apparent persistence of infectivity in 
the environment, and the horizontal transmission by saliva pose serious problems for the 
control or eradication of CWD from herds of captive or wild cervids.  These are likely 
major factors contributing to the high rates of prevalence seen in captive herds [94]. 
Natural transmission to non-cervid species has not been reported.  Many other 
species, both domestic and wild, are known to have been in contact with infected 
cervidae without developing disease [100].   These include cattle, sheep, goats and non-
domestic ruminants such as moose, pronghorn antelope, Rocky Mountain bighorn sheep, 
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mouflon, mountain goats, and blackbuck.  The subsequent identification of CWD in a 
wild moose adds an interesting caveat to the forgoing list.   
The recent demonstration of CWD prion infectivity in skeletal muscle of infected 
deer [101] highlights the point that humans may be exposed to infectious CWD prions by 
consumption of venison.  The question of whether CWD can be transmited to humans has 
not been fully answered, but several studies show it doubtful.  Two reports describing 
epidemiologic investigations both came to the conclusion that there was no strong 
association between consumption of venison and fatal neurologic illness compatible with 
prion disease [102, 103].  In addition, molecular studies of in vitro conversion showed 
that cervid PrPCWD conversion of human PrPC to PrPSC to was very low as compared to 
conversion of cervid PrPC to PrPCWD [104].  A recent review highlighted these studies, 
but also cautioned that much more research was needed concerning this topic [105].   Xie 
et al. compared pathologic profiles and PrPSC characteristics in the brains of CWD-
infected elk and deer with sporadic CJD patients and CJD patients who may have been 
exposed to CWD [106].  This group found that there were some similarities in the size of 
the unglycosylated, proteinase-K resistant core of both human and cervid PrP but that 
there were significant differences in the glycoform ratios and made no association with 
CWD and CJD.  Most conclusively, a study using transgenic expressing human or cervid 
PrP, the humanized mice (previously shown to be susceptible to human prion agents) did 
not develop disease after intracerebral inoculation with PrPCWD whereas the cervidized 
mice developed disease after 118-142 days, leading the authors to conclude that a 
substantial species barrier exists for humans to CWD [107]. 
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The transmission of CWD to cattle is particularly worrisome because of the 
potential economic impact and the potential zoonotic implications due to the association 
between BSE and vCJD.  There are several lines of evidence that demonstrate a species 
barrier preventing natural transmission of CWD to cattle.  Williams reports unpublished 
descriptions of two long term transmission studies to characterize this species barrier 
[108].  In one, cattle confined with CWD-affected deer and elk under experimental 
conditions for over seven years without contracting disease.  In the other, cattle orally 
challenged with brain homogenates from CWD infected mule deer have not shown any 
evidence of transmission after seven years.    Finally, a large scale survey of free ranging 
cattle in a CWD endemic area of  Colorado failed to demonstrate evidence of TSE in any 
of the two hundred sixty-two brains evaluated, leading the authors to conclude that 
transmission of CWD to cattle was unlikely under natural conditions [109].   
The observations showing a barrier to transmission of CWD to cattle via natural 
routes are supported by molecular and intracerebral inoculation studies.  Raymond et al. 
have used a cell free conversion assay to show that CWD-associated PrPCWD readily 
converts cervid PrPC to the abnormal form of the protein, but not PrPC of humans or 
cattle [104].  Conversion of ovine PrPC was intermediate, perhaps indicating a higher 
susceptibility of sheep to CWD.  Experimental transmission by intracerebral inoculation 
of the CWD agent in mule deer brain homogenates to cattle has been accomplished [110, 
111], but the reported transmission rates are relatively low (5 of 13) and histopathologic 
lesions were atypical of a spongiform encephalopathy [111].  In a follow-up study to this 
experiment, Hamir et al. used brain homogenate from one of the affected cattle as the 
inoculum for an additional six calves [112].  This second passage of CWD resulted in 
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disease and euthanasia of all calves by 16.5 months.  Five of the six calves showed signs 
of neurologic disease and all were positive for PrPSC by both IHC and Western blots.  
None of these animals showed microscopic lesions, as with primary transmission.  The 
authors concluded that while transmission of CWD to cattle by intracerebral inoculation 
was possible, but that the lesion profile in infected cattle was distinguishable from BSE 
and that current techniques for diagnosis of BSE in cattle should identify any natural 
transmission of CWD to cattle.   The above work exemplifies the finding that, as with 
other prion diseases, the agent becomes more easily transmitted after primary passage 
into a new species, but the CWD agent seems to be less easily transmitted to rodents on 
first passage than scrapie or BSE [113].  CWD has been successfully transmitted by 
intracerebral inoculation to ferrets, Syrian hamsters, squirrel monkeys, mice, mink, cattle, 
sheep, and goats [108, 114].  Raccoons seem to be resistant to transmission of CWD by 
intracerebral inoculation, and since they are susceptible to TME and scrapie, they have 
been proposed as a model for differentiation of these three agents [115].  Wild-type mice 
also seem to be resistant to CWD and have low primary transmission rates by 
intracerebral inoculation [116].  The recent creation of a transgenic mouse strain 
expressing mule deer prion protein and successful transmission of PrPCWD to these 
transgenic mice opens the door to possible strain typing and bioassay characterization as 
has been done with other TSE agents [116].   
 
Clinical signs 
 The signs associated with CWD are reflected in the name chronic wasting disease, 
a term used by early investigators to describe the observed clinical signs.  Clinical signs 
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described at that time were seen in captive adult deer over two years of age and included 
behavioral alterations, progressive weight loss and death in 2 weeks to 8 months [79].  
Early clinical signs may be subtle; as the disease progresses to terminal stages, signs are 
usually readily apparent.  Aside from weight loss and behavioral changes, animals may 
exhibit sialorrhea, odontoprisis, ataxia, head tremors, esophageal dilatation, regurgitation, 
and aspiration pneumonia [88, 108].  Williams also noted that the terminal signs of CWD 
in elk are less pronounced than those in deer and these include polydipsia and polyuria 
(which may be related to damage to the supraoptic and paraventricular nuclei and 
subsequent diabetes insipidus), and exaggerated behavioral signs such as non-
responsiveness, hyperexcitability, repeated pacing of enclosures, and altered stance with 
lowered head [117].  Sheep with scrapie often exhibit pruritis with subsequent hair loss, a 
feature not noted with CWD.  Williams also reports that deer with subclinical or early 
clinical CWD are susceptible to sudden death after handling and speculated this is related 
to damage to the parasympathetic innervation to the heart, as described in cattle with BSE 
[118].  Death may occur due to aspiration pneumonia, presumably from aspiration of 
excessive saliva or regurgitated ruminal contents due to loss of motor control to the 
esophagus, and CWD should be considered as a differential diagnosis in adult deer with 
aspiration pneumonia  [79, 119]. 
 
Pathogenesis 
The underlying pathogenic mechanism of all prion disease is thought to involve the 
conversion of a normal cellular protein (PrPC) to an abnormal, disease associated form 
(PrPSC).  PrPC is expressed at high levels on the surface of neuronal and lymphoid tissue 
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and to a lesser extent in other tissues [31, 48, 120].  The difference between these 
proteins is thought to be due to dissimilarities in three-dimensional structure, or folding, 
not in the primary amino acid sequence.  The exact function of PrPC is not known, but 
may be important in protection from oxidative stress [121, 122], copper regulation [121, 
123-125], and/or modulation of neuronal excitability [126].  The misfolding of PrPC to 
PrPSC is believed to be induced by PrPSC in either a one-to-one template fashion, or more 
likely through a many-to-one templated (“seeded-template”) reaction [127, 128].  Once 
started, the conversion of PrPC to PrPCWD has been shown to spread both centripetally and 
centrifugally in neuronal tissue [129, 130].   
The toxic principle underlying the pathology noted in the central nervous system is 
not well understood [131].  Major avenues of investigation have focused on a loss of 
normal PrPC function, or gain of toxic function in the conversion of PrPC to PrPSC [132].  
Knockout mouse models deficient in PrPC show very little phenotypic defects and no 
neuronal loss, leading to the conclusion that neuronal toxicity seen in prion diseases is 
probably not due to loss of function of PrPC [126, 133].  Whereas accumulation of 
amyloid in the CNS may account for some of the pathology noted in prion diseases in a 
fashion similar to Alzheimer’s disease [131], chronic deposition of PrPSC by engraftment 
of infected cerebral tissue into the brains of PrP0/0 mice does not elicit disease and does 
not cause histologic lesions in PrP deficient tissue, even in areas immediately adjacent to 
the grafts [134].  Additionally, depletion of PrPC from neurons of scrapie infected mice 
after infection has been shown to prevent disease but not ameliorate the PrPSC formed 
prior to depletion, leading the authors to conclude that propagation of non-neuronal PrPSC 
does not cause toxicity but preventing further conversion prevents neurotoxicity [135].  
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Thus neither loss of PrPC nor the accumulation of PrPSC can fully explain the CNS 
pathology noted in prion diseases.   
GPI associated function may play a pivotal role in the pathogenesis of prion disease 
as recently highlighted by a study in transgenic mice containing a Prnp with a deletion of 
the coding sequence for  the signal peptide responsible for the addition of the GPI anchor 
[136].  When infected with scrapie, these mice did not develop clinical signs of prion 
disease.  Upon necropsy, there were high levels of amyloid accumulation in neural 
tissues.  This suggests that the toxic principle associated with TSEs is related to the GPI 
anchor on PrP, not on the formation of amyloid.  This lends support to the idea that PrPC
acts as a signal transducer through its GPI anchor and interference of this function leads 
to cell death.  This idea is further supported by the observation that cross-linking of PrPC
on the cell surface by antibodies leads to apoptosis [137]. 
Abnormal trafficking of PrPC is one area of research being investigated to understand 
the toxic component of prion disease.  Ma and Lindquist have shown that accumulation 
of PrP in the cytosol in cultured cells and transgenic mice is toxic [138].  In this study, 
misfolded PrP was shown to be retrograde transported from the endoplasmic reticulum to 
the cytosol for degradation by the proteosome.  Accumulation of even small amounts of 
PrP in the cytosol was neurotoxic in cultured cells and transgenic mice.  Thus abnormal 
trafficking by impaired or overwhelmed quality control elements may play an important 
role at the molecular level of prion disease.  Another group has conducted experiments 
studying the topology of PrPC relative to the membrane of the endoplasmic reticulum.  
PrPC can be synthesized in at least three different forms:  1). SecPrP that is fully 
translocated and glycolipid anchored to the membrane, 2). CtmPrP that spans the 
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membrane with its carboxy-terminal domain in the lumen of the endoplasmic reticulum, 
3). NtmPrP that spans the membrane with its amino-terminus in the lumen of the 
endoplasmic reticulum [139].  The CtmPrP has been associated with development of 
neurodegeneration in mice with changes similar to those seen with certain inherited forms 
of human prion disease [139].  This has led to the development of the hypothesis that 
PrPSC triggers formation of CtmPrP in the endoplasmic reticulum and that formation of 
CtmPrP may be the final step toward production of genetic, sporadic, and infectious prion 
disease pathology [140]. 
The pathogenesis of CWD shares many similarities with scrapie [87].  In general, it is 
thought that oral ingestion of the infectious agent leads to early involvement of the gut-
associated lymphoid tissues [98].  Within lymphoid tissues, Sigurdson et al. demonstrated 
PrPCWD on the cell membranes of follicular dendritic cells (FDCs) and possibly B cells, 
and in the cytoplasm of tangible body macrophages within germinal centers, isolated 
macrophages and possibly dendritic cells in perifollicular areas. [141].  Other 
investigators have demonstrated similar findings with scrapie in sheep, vCJD in humans, 
and mouse models of prion diseases [142-153].  Andreoletti et al. identified non-
proliferating macrophages and FDCs as the subset of cells in lymphoid tissue associated 
with scrapie PrPSC using a unique method of dual immunohistochemical labeling of 
scrapie infected sheep [154].  These findings were not noted by Sigurdson, probably due 
to differences in methodologies.  Not all TSEs share this feature of early lymphoid 
involvement, notably BSE in cattle [155] and sporadic or iatrogenic CJD in humans 
[144], a finding which points out the need to interpret findings in one TSE with caution 
when applying to another TSE.   
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Transfer of PrPSC from FDCs to autonomic nerves has been postulated as the route of 
central nervous system infection and has been supported by experiments using transgenic 
mouse models of scrapie [151, 152].   Mabbott et al. showed that depletion of FDCs from 
the spleen of experimental mice prevented the early accumulation of PrPSC and reduced 
disease susceptibility.  In their study, Prinz et al. showed that the relative position of 
FDCs and splenic nerves played an important role in incubation time of disease.  When 
FDCs were juxtaposed near splenic nerves the authors observed acceleration in disease 
progression where as when FDCs were depleted from the spleens of mice, there was a 
decrease in disease progression.  Once in neural tissue, the spread of PrPSC within 
affected animals is thought to occur both centripetally and centrifugally up to and away 
from the central nervous system and subsequently spread to non-lymphoid, non-neuronal 
tissues [130].   
After initial inoculation in cervids, incubation times range from 15 to 36 months [94, 
98, 156].  Affected animals are thought to be infectious soon after exposure and 
throughout the incubation period; agent shedding probably occurs through either feces or 
saliva due to the high levels of PrPCWD in the lymphoid tissues of the gastrointestinal tract 
and the tonsils [48, 96, 157-159].  As with all prion diseases, CWD is invariably fatal. 
 
Gross and microscopic pathology 
 Many of the gross necropsy findings in cervids afflicted with CWD are related to 
loss of body condition and include emaciation, serous atrophy of fat, frothy rumen 
contents, abomasal ulcers, and aspiration pneumonia [79, 81, 108].   
37
The general histologic changes seen in the brain of all species affected with 
transmissible spongiform encephalopathy are very similar and include intraneuronal 
vacuolation, neuronal degeneration and loss, extensive neuropil spongiosis, and astrocytic 
hypertrophy and hyperplasia and occasional amyloid plaques [79, 81, 82, 84, 160].    
These changes are seen to a greater or lesser degree in other forms of prion disease or in 
different areas of the nervous system.  In general, the changes noted in CWD include the 
above with demonstrable amyloid plaques, which are not commonly noted in all forms of 
prion disease [80, 84, 161-164].  CNS lesions are found in the thalamus, hypothalamus, 
midbrain, pons, medulla oblongata, olfactory tubercle, and cortex [79, 81].  PrPC and 
PrPSC have been demonstrated by numerous authors on peripheral nerves [165-170], and 
some studies have demonstrated peripheral neuropathy in transgenic mice with 
genetically induced prion disease [171, 172]. 
Much of the work recognizing and localizing PrPSC at a microscopic level has been 
done with immunohistochemical (IHC) staining using antibodies against prion protein 
and using different treatments to reduce the reactivity of PrPC and increase the reactivity 
of PrPSC [173-176].  IHC has been used to demonstrate the abnormal prion protein in a 
wide variety of tissues, including nervous tissue [177, 178], lymphoid tissue [154, 159, 
179], muscle [180, 181], and endocrine tissue [130].  Studies localizing PrPCWD in mule 
deer seem to demonstrate that PrPCWD accumulation in this species follows a predictable 
pattern [98, 130, 141, 158].  PrPCWD first appears in the gut associated and cranial 
lymphoid tissue and then begins to appear in the central nervous system.  The dorsal 
motor nucleus of the vagus nerve is the first area of the brain to show accumulation of 
PrPCWD before spongiform changes appear or accumulating in other areas [158].  Based 
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upon these consistent findings, Spraker et al. were able to temporally categorize the stage 
(ie. early to late) of infection with CWD in mule deer based upon the distribution pattern 
of PrPCWD and severity of spongiform changes in the brain.  This consistency was not 
found in a study of a large group of captive elk culled in an attempt to prevent the spread 
of CWD [182].  In this study, Spraker et al. found that PrPCWD could accumulate in the 
brain without being found in the lymphoid tissue.  Thus there may be significant 
differences between the pathogenesis of CWD in mule deer and elk and identification of 
infected elk may not be reliable using lymphoid tissue samples.  
 
Epidemiology 
Since CWD was first identified and characterized, there appear to be two different yet 
somewhat interdependent epidemics of CWD:  one in captive cervids that is spread 
through shipment of animals, and one in free ranging cervids that is spread naturally.  In 
the mid 1990s an outbreak of CWD occurred in ranched cervids in North America with 
spread of the disease associated with shipment of animals [83, 183].  This outbreak 
affected ranches in Oklahoma, Kansas, Nebraska, South Dakota, Minnesota, Wisconsin, 
Colorado, Wyoming, Montana, Saskatchewan, and Alberta.  Additional cases were 
associated with this outbreak in animals shipped to South Korea from Canada [85].  The 
disease in free ranging animals was first noted in the contiguous areas of northeastern 
Colorado and southeastern Wyoming and has spread with natural routes of migration and 
movement.  A focus of CWD has been identified in Wisconsin and northern Illinois in 
white-tailed deer that is more likely linked to the occurrence of CWD in ranched deer 
there than extension of the disease due to natural migration [183].  Another focus has 
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been identified in mule deer in southern New Mexico; an area too far removed from any 
known endemic areas or infected game ranches to be plausibly linked to spread from a 
known source.  This outbreak of disease may be related to an unidentified shipment of 
infected animals or a natural outbreak due to some unknown susceptibility factor in this 
population [183]. 
An interesting timeline illustrates the interdependence of these outbreaks (figure 2-3).  
The first reported cases of CWD in wild animals occurred in the area around northeastern 
Colorado and southeastern Wyoming where the first cases of CWD in captive cervids 
occurred. Then the disease appeared in wild cervids in Nebraska in 2000, which could 
plausibly be an extension of the disease by natural migration but CWD was also reported 
in Alberta in 2005, where the only known source was identified as captive herds.  In 
2001, CWD appeared in wild white-tailed deer in Wisconsin and Illinois prior to the 
identification of the disease in captive animals, but positive captive herds were identified 
in Wisconsin the following year.  This appearance in captive and wild animals occurred 
again in 2004 in New York.  Thus, these outbreaks seem to occur together with one 
seeming to serve as a source of infection for the other.  The appearance of CWD in wild 
white-tailed deer in West Virginia in the fall of 2005 has not been associated with any 
captive herds and intense surveillance efforts are currently ongoing in this state. 
 
Control and surveillance 
CWD presents a difficult challenge for controlling and/or eradicating the disease.  
This challenge is due to its occurrence in free ranging, wild species, its seeming ease of 
transmission, its indirect mode of transmission through contaminated environments, and 
40
the seeming ability of the infectious agent to survive and remain infectious for long 
periods [183].  In addition, the occurrence of CWD in captive deer and elk herds has 
provided an artificial environment for both disease amplification and spread [92, 94].  
Due to concern raised by the public about TSEs after BSE was linked to vCJD, many 
state and local governments have instituted surveillance efforts coinciding with annual 
hunter deer harvests.  These surveys have led to the identification of CWD in wild 
animals in Colorado, Wyoming, Nebraska, South Dakota, Utah, New Mexico, Wisconsin, 
Illinois, New York, West Virginia, Alberta and Saskatchewan*. Each year seems to 
expand the list of areas where CWD has been reported in wild cervids. 
Control efforts in captive cervids have primarily centered on slaughter of all animals 
on affected ranches and restriction of movement.  In 1997 the USDA began surveillance 
testing of captive cervid herds for CWD and quarantines were put in place on affected 
herds.  Eradication efforts were implemented in 2001 after sufficient funds were allocated 
for owner indemnification and all known infected ranches were depopulated.  After 
depopulation, owners were advised not to restock these contaminated pastures [156]. 
 
Genetic polymorphism 
The primary structure of the PrPC seems to play a major role in susceptibility to 
misfold into PrPSC. The degree of homology between host PrPC and infectious PrPSC is 
thought to be the basis for the species barrier [184-187].  Prion protein polymorphisms 
can result in susceptible and resistant genotypes and have been well characterized in 
 




sheep [188], and humans [189, 190].  The gene encoding prion protein (Prnp) has been 
published for white-tailed deer, mule deer, elk, and moose.  Polymorphisms have been 
identified in each of these species [21, 191-194].   
In elk, a study of genotypes of animals with CWD identified one polymorphism 
[192].  Interestingly, this polymorphism results from a single amino acid change from 
methionine to leucine at codon 132 (132 M/L) of elk Prnp which is homologous to a 
known human methionine to valine polymorphism at codon 129.  Humans homozygous 
for methionine at codon 129 (129 M/M) are susceptible to iatrogenic and sporadic CJD 
[195], and with one possible exception [196] only 129 M/M homozygotes have been 
diagnosed with vCJD.  In the O’Rourke study, elk homozygous for methionine at codon 
132 were over represented in the CWD positive group, suggesting possible susceptibility 
of this genotype [192].  In a recent study of elk orally inoculated with CWD, two 
homozygous 132 M/M elk showed clinical signs and were euthanized at twenty-three 
months post-inoculation, two heterozygous 132 M/L elk showed clinical signs and were 
euthanized at forty months post-inoculation, and four 132 L/L homozygous elk were 
alive and showed no clinical signs at at least 48 months post-inoculation [197].  The 
above studies suggest that elk homozygous for leucine at codon 132 may be resistant to 
CWD infection.  As with human and ovine TSEs, prion strains may play a role in cervid 
genetic susceptibility, but as yet there have been no reports of different strains of CWD.   
Genetic analysis of alleles conferring resistance or susceptibility to CWD in both 
mule deer and white-tailed deer is complicated by the presence of a processed 
pseudogene in both species [21, 191].  Brayton et al. identified and characterized a 
processed pseudogene in mule deer which lacked introns and was flanked by a direct 
42
repeat indicating it was a retrotransposon [21].  This pseudogene invariably contained an 
asparagine at codon 138 whereas the functional gene encodes a serine at this position.  
After clarifying the confounding issues raised by the pseuodogene, they identified two 
codon polymorphisms in Prnp of mule deer:  an aspartic acid/glycine (D/G) at codon 20 
and a serine/phenylalanine (S/F) at codon 225.  Of the six possible diploid genotypes 
with these alleles, four were found in their study of positive CWD samples (DS-DS, DS-
DF, DS-GS, and GS-GS) indicating that at least these four types were susceptible to 
CWD.  No association was made between CWD susceptibility and pseudogene allele 
types, as expected for this untranslated gene.  One last interesting conclusion from this 
study was that no pseudogenes were found in samples of Old World deer, which included 
Rocky Mountain elk, reindeer, and fallow deer.  The authors postulated three possible 
explanations for this:  1) that sequence diversion had occurred at primer sites for the 
pseudogene that prevented them from detecting it; 2) low pseudogene frequency in these 
species; or 3) establishment of pseudogene after divergence between Old World and New 
World deer more than five million years ago.  A larger study of 1482 free ranging mule 
deer showed an apparent protective effect of heterozyogous S/F at codon 225 and 
concluded that animals with this genotype had a longer incubation period than 
homozygous 225 S/S animals [198]. 
Genotypes in white-tailed deer are similarly complex [24, 104, 191, 193].  O’Rourke 
et al. noted five major diploid genotypes and four rare genotypes in a study of one 
hundred thirty-three wild white-tailed deer.  These genotypes were defined by three 
amino acid substitutions previously noted by others:  glutamine/histidine (Q/H) at codon 
95, glycine/serine (G/S) at codon 96, and alanine/glycine (A/G) at codon 116.  This study 
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identified a pseudogene similar to the one in mule deer, and this pseudogene could be 
differentiated by the substitution of an asparagines/serine (N/S) at codon 138.  The two 
most common alleles (QGAS and QSAS at codons 95, 96, 116, and 138) of the functional 
gene comprised almost 90% of the total.  Although all genotypes identified were affected 
by CWD, there was some evidence that QGAS was more susceptible than QSAS.  No 
association was made between the pseudogene and presence of disease.  Recently, large 
study of white-tailed deer identified another polymorphism at codon 226 encoding 
glutamine/lysine (Q/K), and further characterized the comparative protective effect of 
polymorphism to susceptibility to CWD [199].  These authors concluded that 96 G/S and 
95 Q/H were linked to a reduced (but not complete) susceptibility to CWD and that the 
96 G/S allele was linked to slower progression of disease. 
A brief report of polymorphism in Alaskan moose (Alces alces gigas) describes one 
unique amino acid polymorphism at codon 209 identified in a population of 44 moose.  
This polymorphism resulted in one allele with methionine that occurred with a frequency 
of 0.45 and one with isoleucine that occurred with a frequency of 0.55 [194].  The 
corresponding amino acid for all three other species of cervids known to be susceptible to 
CWD is methionine.  The relationship of this polymorphism to disease susceptibility is 




The current gold standard for diagnosis of CWD is immunohistochemistry (IHC) of 
the obex or ‘specific lymphoid tissue’ [200].  Several commercial test kits have been 
approved for rapid screening of CWD samples utilizing enzyme-linked immunosorbent 
assay (ELISA) technology and proteinase K digestion.  All of these methods are 
dependent upon antibody recognition of PrPSC after removal of PrPC from samples.  The 
rapid tests are primarily ELISA and Western blot after sample digestion with proteinase 
K except for one unique technology marketed by IDEXX that utilizes a novel capture 
ligand (a proprietary polyanionic molecule termed Seprion) that preferentially binds 
PrPSC but not PrPC. Official tests for CWD are performed with a rapid screening test and 
suspects are confirmed using IHC or Western blot at USDA approved laboratories.  
Testing for BSE is done in a manner similar to CWD:  large numbers of samples are 
screened with high-throughput rapid tests and confirmation of suspects is done with IHC 
or Western blot. Testing of lymphoid tissue is not possible with BSE due to the apparent 
lack of lymphoid involvement [155].  This section will discuss the current state of testing 
for CWD, possible alternative approaches currently under development, and the use of 
bioassays for prion disease. 
The diagnosis of CWD (or any TSE) is complicated by the lack of antibody response 
in infected individuals that makes serologic diagnosis of prion disease impossible.  This 
lack of antibody response is apparently due to self tolerance of PrPC [201] and is reflected 
in the fact that antibodies available to date can not distinguish PrPSC from PrPC. Reports 
of monoclonal antibodies specific for PrPSC have been published [202, 203], but have not 
been applied in a diagnostic setting.  
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Great progress has been made in improving and adapting the somewhat cumbersome 
methodology of PrPC removal and subsequent identification of remaining PrPSC with 
anti-PrP antibodies.  Identification of PrPSC in post-mortem tissue of animals in late 
stages of infection is possible with existing technologies, but ante-mortem identification 
of infected individuals, especially those in the early incubation stage where PrPSC levels 
are very low, remains a difficult problem.  The use of tonsillar biopsy to diagnose CWD 
has value as an antemortem test in some high value captive cervids, but the restraint 
necessary to obtain sample material makes it impractical in most situations.  The use of 
lymphoid tissue alone for diagnosis of CWD in elk is not recommended, as 10-15% of 
samples may show PrPCWD in neurologic tissue but not in lymphoid tissue [108].  
Diagnosis of scrapie in sheep has been accomplished by third eyelid biopsy, but this 
technique has not proven useful in cervid species because the lymphoid tissue present in 
the third eyelid is sparse and difficult to evaluate [108].   Thus, a great need exists for 
diagnostic methods that can be applied to easily accessible samples such as blood or urine 
in an ante-mortem test. 
Several alternative markers of prion disease have been described in humans for CJD 
such as protein 14-3-3, S-100, and neuron specific enolase but these markers are not 
specific for CJD and are known to be elevated in other neurologic diseases [204-206].    
All of these markers have been used as ancillary indicators to raise the clinical suspicion 
of prion disease primarily in human patients. 
 An exception to the need to separate PrPSC and PrPC prior to assay is the 
conformation dependent immunoassay (CDI) that utilizes differential antibody binding 
under native and denaturing conditions [207].  Briefly, under native conditions certain 
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antibodies bind to PrPC with more affinity than PrPSC but when the samples are denatured 
with guanidine, certain epitopes become exposed on PrPSC that lead to a different binding 
signal.  The difference in signal under native and denaturing conditions is used to identify 
samples containing PrPSC. This test has been approved for use in Europe, but has not 
gained widespread acceptance.  The CDI can be used to measure PrPSC levels could be 
detected with similar sensitivity to the infectious titers measured in a mouse bioassay 
[207].  The only drawback preventing widespread use of the CDI seems to be its 
technical complexity. 
A unique strategy to amplify low copy numbers of PrPSC to detectable levels in a 
manner analogous to the polymerase chain reaction is the cyclic amplification of a PrPC
template by PrPSC in a sample [208, 209].  This method, termed protein misfolding by 
cyclic amplification (PMCA) has recently been used to greatly amplify PrPSC from an 
original sample to increase sensitivity of detection [210].  Additionally, this method has 
been used to generate infectious PrPSC that was shown to induce disease when injected 
back into laboratory animals at limiting dilutions for the original PrPSC [11]. 
The novel diagnostic challenge presented by TSEs is being met by some very novel 
techniques to detect PrPSC. The developers of the Seprion ligand claim to be able to 
detect PrPSC in blood samples utilizing this technology [211], but have not published their 
findings in refereed literature.  If this claim is true, it would answer long sought needs in 
the realms of protecting the blood supply as well as ante-mortem diagnosis of prion 
disease.  Another novel approach to detecting PrPSC is the use of a circulating nucleic 
acids test protocol that can identify BSE susceptible animals through comparative 
analysis of nucleic acids amplified with degenerate primers of both normal and BSE 
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positive cattle [212].  A third unique approach, termed the misfolded protein diagnostic 
assay (MPD) uses fluorescently labeled peptides that interact with PrPSC and undergo a 
conformational change that can be detected by a change in the fluorescent signal [213].  
Another group has used fluorescently labeled peptides in a competitive antibody binding 
assay for PrPSC detected with capillary electrophoresis [214, 215].     
Another novel approach is the use of aptamers, single stranded DNA or RNA 
oligonucleotides, as diagnostic probes for PrPSC [216].  Aptamers recognize their target 
molecules through non-covalent interactions similar to the way antibodies interact with 
epitopes, but aptamers are selected in an in vitro process termed SELEX (Systematic 
Evolution of Ligands by EXponential enrichment) whereby the target molecule is 
allowed to interact with a pool of oligonucleotides and those oligonucleotides with a 
binding affinity are recovered and amplified via PCR [217]. 
Several groups have selected aptamers to the prion protein.  Weiss et al. selected  
RNA aptamers using recombinant hamster prion protein as the target and showed that 
these aptamers interacted with the amino acids 23-52 of prion protein [218].  These 
aptamers were shown to specifically interact with prion protein by supershift assays 
performed on brain homogenates of non-infected mice, hamsters and cattle, but the 
aptamers did not recognize PrPSC in an assay using the proteinase K resistant core of 
PrPSC. Proske et al. subsequently selected RNA aptamers using a peptide representing 
amino acid residues 90-124 and showed that these aptamers could reduce the conversion 
of PrPC to PrPSC in a conversion assay [219].   In an attempt to select PrPSC specific 
aptamers, a third group use preparations of PrPSC as the target molecule [220].   They 
then produced recombinant peptides biochemically folded into alpha helix rich or beta 
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sheet rich conformations (representing PrPC and PrPSC respectively) to show that their 
aptamers could specifically recognize the PrPSC conformation with an affinity ten times 
greater than PrPC. These aptamers also inhibited formation of PrPSC in a conversion 
assay. The binding of one of these aptamers was mapped to amino acid residues 23-110 
and another C terminal to residue 110.   Sekiya et al. have selected an RNA aptamer 
using recombinant mouse PrP as the target and showed that it had a high affinity (K(d) = 
5.6 +/- 1.5 nM) for the recombinant PrP and mapped it’s binding site between amino 
acids 23-108 [221].  This group also claims to have selected an aptamer to PrPSC and 
demonstrated evidence for this in a modified blotting method [222] using immobilized 
PrPSC and radiolabeled aptamer as the probe.  Takemura et al. selected DNA aptamers 
using recombinant human PrP and demonstrated binding to both recombinant PrP and to 
PrPC derived from healthy sheep, calf, piglet, deer, and mouse neuroblastoma cells [223].  
These aptamers did not recognize PrPSC prepared by proteinase K digestion.  Another 
group has adapted a PrPSC specific aptamer for use in capturing PrPSC from biological 
samples and has made claims to be able to detect PrPSC from antemortem blood samples, 
although these findings have not been published in refereed literature [224, 225]. 
There is much evidence that prion protein interacts with nucleic acids and that this 
interaction may play a role in conversion from PrPC to PrPSC [226-232].  In an attempt to 
clarify the structural sequences for the previously identified property of PrPC to bind to 
nucleic acids, Mercey et al. used recombinant ovine PrP to select RNA aptamers and 
studied the rates of interaction of these aptamers with recombinant PrP [233].   They also 
identified two lysine rich regions of PrP that specifically interacted with one of the 
aptamers contained within the amino acid residue 25-34 and 101-110.  Interestingly, the 
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sequence of this aptamer showed high sequence homology to two other aptamers 
previously identified – one selected by Proske et al. [219] and the one selected by Rhie et 
al [220].   As evidenced by the fact that most characterized aptamers to PrP selected to 
date bind to residues lying between 23-110 and do not specifically recognize PrPSC, this 





Much of the early work diagnosing and characterizing the infectious agent of 
TSEs was accomplished with animal bioassays, and bioassays remain an essential tool in 
prion disease research and diagnosis.  The successful transmission of scrapie to mice by 
intracranial inoculation allowed investigators to more easily quantify and detect prions 
[234].  Animal bioassays are very time consuming and can be limited by the species 
barrier and yet they remain the most sensitive method of detecting prions.  The creation 
of PrP knockout, mutant, and transgenic mice has vastly improved the usefulness of 
animal bioassays as a tool for studying prion disease [207, 235].  Many of the 
observations made about different strains of TSEs have been made using animal 
bioassays and the recent creation of a transgenic mouse expressing cervid PrP [116] 
allowed researchers to demonstrate of the presence of infectious prions in skeletal muscle 
of CWD infected deer [101], something that was not possible with IHC [236].  This 
demonstrates the greater sensitivity of bioassays.   
Cell cultures that support replication of prions represent an alternative to animal 
bioassay [237, 238].  Cell culture models have been used to investigate the cell biology of 
PrPC and PrPSC, and these studies have provided a great deal of insight into the normal 
and disease associated trafficking of PrP inside the cell [239-241].  Cell culture models 
have also proven extremely useful in therapeutic drug screening and have been used to 
identify many potential drug candidates, although to date none has proven useful 
clinically [242-244].  In addition to basic molecular biology studies and therapeutic drug 
screening, one cell culture model of prion disease has been used as a diagnostic assay to 
both identify and quantify infectious murine prions [245].  A recent review of cell culture 
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models lists nine neural cell lines and seven non-neural cell lines permissive to prion 
replication [246].  By far the most common cell line used in published studies is the 
persistently infected line N2a, a line infected with mouse-adapted Chandler strain of 
scrapie.  Many investigators are attempting to develop specific TSE agent permissive 
cultures, and this has resulted in a recent line of brain derived fibroblasts that are 
persistently infected with CWD [247].  Cell culture models of prion disease hold great 
promise for detection, characterization, and intervention studies of prion disease. 
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Conclusion 
 CWD is a growing problem in North American cervids.  It is a unique 
transmissible spongiform encephalopathy in that it is the only known such disease 
occurring in a wild, free ranging population.  As with other prion diseases, CWD presents 
many novel scientific problems involving elucidation of pathogenesis, diagnosis, and 
even the disease agent itself.  Major areas of concern and future research involve 
development of diagnostic assays which are robust and performed on easily accessible 
samples such as blood or urine, development of cell based models, the clarification of 
potential zoonotic transmission and transmission to economically important domestic 
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Figure 2-1.  Schematic of mule deer Prnp. 
Exon 1 - 54 bp
Exon 2 - 98 bp Exon 3 - 4083 bp




Figure 2-2.  Schematic of elk PrPC.  Important areas of the protein and associated amino acid 
position.  Large arrows = β sheet 1 and 2 (positions 130-133 and 163-166 respectively).  
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Figure 2-3.  Illustrative time line of reported incidence and location of CWD in captive and wild 
cervids in North America. 
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The objective of this study was to select a specific molecular probe, called an 
aptamer, to identify the disease associated, misfolded isoform of prion protein (PrPCWD)
in samples submitted for diagnosis of chronic wasting disease (CWD) in cervid species.  
Identification of PrPCWD is complicated by the fact that it differs from the normal prion 
protein (PrPC) only in secondary and tertiary structure whereas the primary amino acid 
sequence is the same.  Aptamers are oligonucleotides (either single-stranded DNA or 
RNA) that can recognize target molecules through three dimensional interactions similar 
to the way antibodies recognize an epitope, and they are selected from very diverse 
starting pools of randomly generated, synthetic oligonucleotides in a cyclic process 
termed SELEX (Systematic Evolution of Ligands by EXponential enrichment).  In this 
process, the target molecule is allowed to interact with a pool of oligonucleotides and 
those oligonucleotides that bind to the target are recovered and amplified via PCR.  This 
amplified pool then serves as the new pool for target interaction, and the cycle is 
repeated.  Once selected, aptamers can have dissociation constants in the low nanomolar 
range, very similar to antibodies.  Aptamers have advantages over antibodies in that they 
are prepared synthetically and can be relatively easily modified and adapted to various 
sensing platforms.  Aptamers have been selected to PrPSC (an abnormal isoform of PrP, 
like PrPCWD, associated with scrapie), and have been used to inhibit conversion of PrPC to 
PrPSC in a conversion assay, but they have yet to be applied as a diagnostic reagent.   
We proposed to select aptamers which can differentiate PrPC from PrPCWD. Due 
to the inability to completely remove PrPC from our target sample, a cross-over strategy 
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was used based upon enriching a pool for species with affinity for PrPCWD and removing 
species with an affinity for PrPC through negative selection. 
One of the most critical aspects of SELEX experiments is the method of 
partitioning bound from unbound oligonucleotides.  We have used two primary methods 
of partitioning that we termed electrodialysis SELEX and targeted epitope SELEX.  The 
electrodialysis strategy is based upon differential mobility of PrPCWD-bound and unbound 
oligonucleotides inside a dialysis membrane placed in an electrophoretic field.  The 
targeted epitope strategy is based upon presenting epitopes thought to be differentially 
surface exposed in the two isoforms of PrP grafted into the complimentarity determining 
region of a monoclonal antibody. 
We identified an aptamer using electrodialysis SELEX (aptamer 15-8) that binds 
to both forms of prion protein as shown by comparative binding to bovine serum albumin 
as a negative control.  Additonally, aptamer 15-8 shows binds to prion protein two to four 
times higher for E. coli single stranded DNA binding protein.  We also identified three 
potential candidate aptamers using targeted epitope SELEX (A8, A11, and B55) based 
upon their enrichment in the final pool and the similarity of their sequences to previously 
published aptamers to PrP.  Binding assays for these three aptamers are currently 
underway and will be included in the final manuscript. 
In conclusion, we have developed two novel methods of aptamer selection termed 
electrodialysis SELEX and targeted epitope SELEX and have used these methods to 
select aptamers based upon their binding affinity for PrP or their enrichment in the final 
pool and similarity to other PrP aptamers. 
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Introduction and background 
Chronic Wasting Disease (CWD) is a transmissible spongiform encephalopathy 
(TSE) that affects mule deer (Odocoileus hemionus hemionus), Rocky Mountain elk 
(Cervis elaphus nelsoni), white tailed deer (Odocoileus virginianus), and moose (Alces 
alces) in North America.  Other TSEs include Kuru, Creutzfeld Jakob’s disease (CJD) 
and variant Creutzfeld Jakob’s disease (vCJD) of humans; bovine spongiform 
encephalopathy (BSE) of cattle; scrapie of sheep; and transmissible mink encephalopathy 
(TME).  These diseases are also called prion diseases because they are thought to be 
caused by a unique transmissible agent termed a prion [8].  The underlying molecular 
event involved in the pathogenesis of TSEs is the conversion of a normal cellular protein, 
prion protein (PrPC), to an abnormal (yet stable) conformation (PrPSC) that acts as a 
template for futher PrPC misfolding [248]. 
Currently approved rapid methods of transmissible spongiform encephalopathy 
(TSE) diagnosis rely upon antibody recognition of the prion protein, but thus far no 
antibodies that differentiate PrPC from PrPSC have been applied in a diagnostic setting.  
Samples are first treated with proteinase K to remove PrPC, leaving the relatively 
proteinase K resistant PrPSC. The samples are then probed with anti-prion antibodies to 
detect residual PrPSC. Although these rapid molecular methods have found great utility in 
identifying TSE infected animals post-mortem and some have been used in ante-mortem 
diagnosis by identifying PrPSC in lymphoid tissue [179], a need exists for rapid ante-
mortem tests to identify TSE infected animals. 
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Aptamers represent an alternative to antibodies as molecular probes.  Aptamers 
are oligonucleotides (either single-stranded DNA or RNA) which can recognize target 
molecules through three dimensional interactions similar to the way antibodies recognize 
an epitope [217].  They are selected from very large starting pools of randomly generated, 
synthetic oligonucleotides.  The starting pool diversity is dependent upon the length of 
the oligonucleotide and is usually on the order of 1013-15 unique sequence species.  
Aptamers are selected in a cyclic process termed SELEX (Systematic Evolution of 
Ligands by EXponential enrichment) whereby the target molecule is allowed to interact 
with a pool of oligonucleotides, and those oligonucleotides which bind to the target 
molecule are recovered and amplified via PCR (figure 3-1).  The DNA strands are then 
separated, and this amplified, single stranded pool serves as the new pool for target 
interaction and the cycle is repeated.  Once selected, aptamers have been shown to have 
dissociation constants similar to antibodies, but have the advantages in that they can be 
prepared synthetically and can be relatively easily modified and adapted to various 
sensing platforms.   
Several groups have selected aptamers to the prion protein.  Weiss et al. selected  
RNA aptamers using recombinant hamster prion protein as the target and showed that 
these aptamers interacted with the amino acids 23-52 of prion protein [218].  These 
aptamers were shown to specifically interact with prion protein by supershift assays 
(retardation of electrophoretic migration) performed on brain homogenates of non-
infected mice, hamsters and cattle, but the aptamers did not differentiate the two isoforms 
of PrP or recognize PrPSC in an assay using the proteinase K resistant core of PrPSC. This 
core is comprised of amino acid residues 90-231 due to cleavage of PrPSC after amino 
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acid 89.  No interaction was noted with supershift assays performed on brain 
homogenates of PrP0/0 mice or with scrambled aptamer species on brain homogenates of 
wild-type mice, demonstrating the specificity of the aptamers for PrP.  Proske et al. 
subsequently selected RNA aptamers using a peptide representing amino acid residues 
90-124 and showed that these aptamers could  reduce the conversion of PrPC to PrPSC in a 
conversion assay using prion infected mouse neuroblastoma cells [219].   In an attempt to 
select PrPSC specific aptamers, Rhie et al. used preparations of PrPSC as the target 
molecule [220].   They then produced recombinant peptides biochemically folded into 
alpha helix rich or beta sheet rich conformations (representing PrPC and PrPSC 
respectively) to show that their aptamers could specifically recognize the PrPSC 
conformation with an affinity ten times greater than PrPC. These aptamers inhibited 
formation of PrPSC in a cell-free conversion assay. The binding of one of these aptamers 
was mapped to amino acid residues 23-110 and another to regions of PrP C terminal to 
residue 110.   Sekiya et al. have selected an RNA aptamer using recombinant mouse PrP 
as the target and showed that it had a high affinity (K(d) = 5.6 +/- 1.5 nM) for the 
recombinant PrP and mapped it’s binding site between amino acids 23-108 [221].  This 
group also claims to have selected an aptamer to PrPSC and demonstrated evidence for 
this in a modified blotting method [222] using immobilized PrPSC and radiolabeled 
aptamer as the probe.  Takemura et al. selected DNA aptamers using recombinant human 
PrP and demonstrated binding to both recombinant PrP and to PrPC derived from healthy 
sheep, calf, piglet, and deer brain tissue and mouse neuroblastoma cells [223].  These 
aptamers did not recognize PrPSC prepared by proteinase K digestion, indicating that their 
binding site lies in the N terminal unstructured region of PrP. 
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There is much evidence that prion protein interacts with nucleic acids and that this 
interaction may play a role in conversion from PrPC to PrPSC [226-232].  In an attempt to 
clarify the structural sequences for the previously identified property of PrPC to bind to 
nucleic acids, Mercey et al. used recombinant ovine PrP to select RNA aptamers and 
studied the rates of interaction of these aptamers with recombinant PrP [233].  They also 
identified two lysine rich regions of PrP, at amino acid residues 25-34 and 101-110, that 
specifically interacted with one of the aptamers.  Interestingly, the sequence of this 
aptamer showed high sequence homology to two other aptamers previously identified – 
that selected by Proske et al. and the one selected by Rhie et al [233].  As evidenced by 
the fact that most characterized aptamers to PrP selected to date bind to residues lying 
between 23-110 and do not specifically recognize PrPSC, this region may contain a 
nucleic acid binding epitope that masks selection of a PrPSC specific aptamer. 
The purpose of this study was to select aptamers that can differentiate the 
misfolded, disease-associated PrPCWD (PrPSC of chronic wasting disease) from the normal 
PrPC of elk and deer.  Identification of such an aptamer would provide a long sought 
reagent that could be applied directly to diagnostic samples without the need for prior 
digestion with proteinase K.  The selection of PrPCWD-specific aptamers presents three 
primary problems:   
1) The two isoforms of PrP differ only in their secondary and tertiary structure and 
therefore specific aptamers must recognize differentially exposed epitopes on 
PrPCWD.
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2) A method to completely purify preparations of PrPCWD that are free of PrPC has 
not been described.  Therefore, utilizing PrPCWD as a target for SELEX will also 
have a low level of PrPC that serves as a target.  
3) The nucleic acid binding properties of PrP may mask selection of aptamers 
specific to the PrPCWD conformation.  
Although the difference between the two isoforms of PrP has been shown to 
reside in the secondary and tertiary structure of the protein, purification and 
crystallization of PrPSC has thus far not been accomplished, so the exact structure of this 
isoform remains unsolved and differentially exposed epitopes are not clearly identified.  
To select aptamers for such differentially exposed epitopes on PrPCWD, two primary 
categories of target were used:   
1) Enriched preparations of PrPCWD with removal of PrPC-binding aptamers through 
a process termed negative selection.  This negative selection is directed at 
removal PrPC-specific binding species and species that can recognize both 
isoforms of PrP. 
2) Highly purified preparations of epitopes predicted to be differentially exposed in 
the form of cellulose immobilized peptides or motif grafted antibodies.   
A total of three different selection strategies have been used in an attempt to 
identify PrPCWD-specific aptamers (see table1).  In strategy #1, a predicted surface 
exposed epitope of PrPCWD [202] was used as a target to select specific aptamers.  This 
epitope was used to generate PrPSC specific antibodies by Paramithiotis et al., and was 
immobilized onto derivatized cellulose membranes using a commercially available kit 
(SPOTs™, Sigma Genosys).  Strategy #2 was devised in an attempt to exclude the 
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complication of an immobilization substrate serving as an alternative target for 
oligonucleotide binding.  PrPCWD and recombinant PrP (rPrP) were used as positive and 
negative targets respectively, aptamers were allowed to interact with the targets in 
binding buffer, and separation of binding from non-binding species was accomplished by 
electrophoretic migration across a selective dialysis membrane.  Strategy #3 utilized 
motif-grafted antibodies obtained from Dr. R. Anthony Williamson at the Scripps 
Research Institute, La Jolla California as selection targets.  These antibodies are 
engineered to contain polypeptides corresponding to residues 89-112 or 136-158 of the 
mouse prion protein (residues 94-115 and 140-162 of elk prion protein) in the 
complementarity-determining region 3 of the heavy chain of a monoclonal mouse IgG 
specific for the envelope glycoprotein of HIV-1 [137].  These regions on PrP have been 
shown to be critical for the heterodimeric association of PrPC and PrPSC and are thought 
to represent differentially exposed epitopes on the two isoforms of the protein.  Recent 
evidence suggests that IgG 89-112 specifically recognizes PrPSC and further testing of 
this is ongoing [249].  Strategy #1 was found to be non-specific very early in the SELEX 
process, but we were able to complete a total of fifteen rounds of SELEX with 
electrodialysis SELEX and twenty rounds of selection with targeted epitope SELEX. 
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Materials and methods 
DNA Aptamer Library 
All oligonucleotides were purchased from Integrated DNA Technologies.  The 
DNA aptamer library was composed of a randomized 30 nucleotide central region 
flanked by constant, twenty-four nucleotide primer binding sites.  The sequence of the 
library was: 
5′- AGCAGCACAGAGGTCAGATG (N30) CCTATGCGTGCTACCGTGAA-3′
The notation (N30) represents the randomized central region. The sequence of the 
forward primer was 5′- AGCAGCACAGAGGTCAGATG-3′. The sequence of the 
reverse primer was 5′- TTCACGGTAGCACGCATAGG-3′. For urea PAGE strand 
separation (see below), a twenty nucleotide poly-adenosine was added to the 5′ end of the 
anti-sense primer separated by a double tri-ethylene glycol spacer to prevent extension by 
Taq polymerase and make the reverse strands 20 nucleotides longer than the forward 
strand.  For strand separation using streptavidin coated paramagnetic beads, a 5′ biotin 
was added to the reverse primer. 
 
Polymerase chain reaction amplification of oligonucleotides 
Amplification of oligonucleotides with randomized sequences was optimized by 
testing different annealing temperatures, polymerase enzymes, cycling parameters, and 
magnesium concentration to produce a set of parameters yielding specific amplification 
of desired products with little to no production of high molecular-weight parasite species.  
The final optimized protocol was performed using Immolase™ DNA Polymerase from 
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Bioline according to the following cycling conditions: 94°C X 7 minutes (initial enzyme 
activation), 30 cycles of 62°C X 30 seconds, 72°C X 30 seconds, 94°C X 30 seconds.  
Optimized concentrations of other components of the reaction included MgCl2 at 2.5 
mM, primers at 1 µM each, dNTP concentration 0.5mM each, and enzyme at 2 units per 
100µL reaction volume.  To facilitate strand separation for generation of single stranded 
oligonucleotides, the reverse primer was either 5′ biotinylated or contained a non-
extendable poly-adenine 20mer added to the 5′ end.  
 
Purification of PrPCWD 
Enrichment for the disease associated form of elk PrP was performed using two 
primary methods – sodium phosphotungstic acid precipitation and  proteinase K 
(Worthington Biochemical Corporation) digestion according to the methods of 
Wadsworth et al. [250] or ultracentrifugation essentially according to the methods of 
Bolton et al. [251].  The ultracentrifugation method was used to prepare targets for 
SELEX because proteinase K cleaves PrPSC at approximately amino acid 90 and the full 
length protein was deemed a more appropriate target.  This method has been shown to 
greatly enrich preparations for PrPSC without detectable PrPC [251] 
 
Sodium Phosphotungstic Acid Precipitation of PrPCWD.
Brain homogenates were prepared by suspending one gram brain tissue from a known 
CWD positive elk (kindly provided by Dr. Katherine O’Rourke, USDA ARS, Pullman, 
WA) in 10 mL sterile Dulbecco’s PBS without Ca2+ or Mg2+ using a tissue 
homogenizer.  Cellular debris were removed by centrifugation at 80g for 1 minute.  The 
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supernatant was mixed with an equal volume of 4% sarkosyl in PBS pH 7.4 and 
incubated for 10 minutes at 37°C.  Benzonase® (Merck) and MgCl2 were added to final 
concentration of 50 units/mL and 1mM respectively and the sample was incubated at 
37°C for 30 minutes.  Sodium phosphotungstic acid (PTA, Sigma Aldrich) in MgCl2 was 
added to give a final concentration of 0.3% (w/v) PTA and incubated a further 30 minutes 
at 37°C.  The sample was centrifuged at 15,800g for 30 minutes at room temperature.  
The supernatant was removed, and the pellet resuspended in PBS with 0.1% sarkosyl pH 
7.4 and 50 mM EDTA (to solublize precipitated magnesium salts).  The sample was 
centrifuged for 15 minutes at 15,800g, and the resulting pellet resuspended in PBS with 
0.1% sarkosyl pH 7.4.  The protein concentration of each PrPCWD preparation was 
determined by BCA assay. 
 
Ultracentrifugation preparation of PrPCWD 
One gram of brain tissue was suspended in 10 mL of ice cold buffer (10mM Tris-HCl, 
1mM EDTA, 133mM NaCl, 1 mM DTT, 10% (w/v) sarkosyl (Sigma Aldrich), pH 8.3).  
The tissue was homogenized with a ground glass tissue homogenizer.  This 10% brain 
homogenate was then centrifuged at 22,500g using a Beckmann 45Ti rotor for 30 minutes 
at 4°C.  The supernatant was recovered and further centrifuged at 150,000g for 3 hours at 
4° C.  The supernatant was discarded, and the pellet was resuspended in buffer (10 mM 
Tris-HCl, 1mM EDTA, 10% (w/v) NaCl, and 1% (w/v) sarcosyl by ultrasonication using 
a cup-horn probe until the pellet appeared totally resuspended.  The volume was then 
brought to approximately 1.5 mL and centrifuged at 225,000g for 2 hours at 20° C.  The 
supernatant was discarded, and the pellet resuspended in 10 mM Tris-HCL, 100 mM 
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NaCl, 5 mM CaCl2, 5mM MgCl2, pH 7.4 by ultrasonication using a cup horn probe until 
the pellet appeared totally resuspended.  RNAse A (100ug/mL, Sigma Aldrich) and 
DNase I (20 ug/mL, Sigma Aldrich) were added to the resuspension and digestion was 
carried out overnight (~12 hours) at 4° C.  The concentrations of EDTA, NaCl, and 
sarkosyl were brought to final concentrations of 20 mM, 10% (w/v), and 1% (w/v), 
respectively, and this suspension was centrifuged at 225,000g for 2 hours at 20° C.  The 
resulting pellet was resuspended in water by sonication at the highest setting in a cup 
horn probe in fifteen second bursts until no visual precipitate remained.  Aliquots were 
frozen at -20° C and thawed as needed for use. 
 
SDS PAGE and Western blot 
Two mg equivalents (the volume of final preparation representing two mg of the 
starting brain homogenate) of PrPCWD were mixed with an equal volume of 2X Laemmeli 
sample buffer (Sigma Aldrich).  The samples were heated to 95°C for 5 minutes and 
loaded onto a 15% polyacrylamide gel.  The gels were placed into a vertical 
electrophoresis apparatus (Mini-Protean 3, BioRad), and current was applied at 80 volts 
for approximately 1 hour until the dye front reached the bottom of the gel.  The proteins 
were then transferred to nitrocellulose using a submersible blotting apparatus (Criterion 
blotter, BioRad) set to 100 volts for 30 minutes.  The membranes were blocked with a 
commercially available blocking reagent (Superblock® Blocking Buffer in TBS, Pierce) 
for 1 hour at room temperature.  Anti-PrP monoclonal antibody F89/160.1.5 (Abcam) 
was diluted 1:200 in blocking buffer and incubated with the membrane for 1 hour at room 
temperature.  The membranes were washed 5 X 5 minutes with 0.05% Tween in Tris 
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buffered saline (TTBS) and then probed with HRP conjugated goat anti-mouse IgG 
(Abcam ab6789) diluted 1:10,000 for 1 hour at room temperature.  The membranes were 
washed again 5 X 5 minutes with TTBS, and chemiluminescent substrate (SuperSignal 
West Femto® Pierce) was added for five minutes.  The membrane was then placed inside 
a plastic sheet and imaged using a Storm 860 Molecular Imager (for ultracentrifugation 
preparations, performed in the laboratory of Dr. Jason Bartz, Creighton University) or 
exposed to radiographic film for 30 seconds to one minute.  The radiographic film was 
developed using a Kodak automatic processor. 
 
Radiolabeling of oligonucleotides 
For different experiments, the pool of oligonucleotides or specific aptamers were 
radiolabeled by either 5' end labeling with a commercially available kit (Optikinase™, 
USB) using [γ-33P]ATP or body labeled by PCR amplification with a source of [α-33P] 
ATP.   
 
5' end labeling 
Specific selected oligonucleotides were radiolabeled by phosphate exchange using 
a recombinant T4 Polynucleotide Kinase (Optikinase).  Five pmol of the pool was 
incubated with 10 units of Optikinase, 5 pmol [γ-33P]ATP, and Optikinase buffer 
(containing an excess of ADP) at 37°C for 30 minutes.  The enzyme was inactivated by 
heating to 65° C for 10 minutes, and the radiolabeled oligonucleotides were purified 
using Sephadex G-25 columns (Amersham) following manufacturers directions.   
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Body labeling of oligonucleotides by PCR 
Pools of oligonucleotides were labeled by amplification in the presence of a 
source of [α-33P]ATP according to the methods of Esposito et al. [252].  In general, 
limiting the concentration of [α-33P]ATP relative to the concentration of other dNTPs 
resulted in higher specific activity but also lower total yield of DNA.  Optimization 
experiments were carried out comparing different activities and yields at different ratios 
of [α-33P]ATP:dNTPs and showed that a 1:2 ratio resulted in the highest yield with high 
specific activity. 
 
Cellulose Immobilized Peptides SELEX 
A peptide motif consisting of tyrosine-tyrosine-arginine (YYR) was immobilized 
in duplicate with a tri-glycine spacer on cellulose using a commercially available kit 
(SPOTs Sigma-Genosys).  The final peptide from the immobilization substrate was G-G-
G-Y-Y-R-Y-Y-R at a theoretic concentration of 8 nmole per spot.  The cellulose spot was 
cut out and incubated with an equimolar concentration of DNA aptamer pool (prepared 
by heating to 95°C for 5 minutes, then cooled to room temperature for ten minutes) in 
HMKN buffer (20mM Hepes, 10mM MgCl2, 50mM KCl, 100mM NaCl pH 7.2) for 1 
hour.  The membrane was removed and washed three times with HMKN buffer.  The 
washed membrane was then cut into different size pieces and added to 100 uL of PCR 
master mix for amplification of bound oligonucleotides using biotinylated anti-sense 
primer.  The double stranded PCR product was then bound to paramagnetic streptavidin 
beads (Dynal Dynabeads® M270, Invitrogen).  The beads were washed twice with PBS 
then resuspended in double distilled water.  This suspension was then heated to 95°C for 
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5 minutes to melt the strands apart, flash cooled in ice/ethanol to prevent re-annealing, 
placed on a magnetic stand, and the supernatant removed from the beads quickly.  The 
concentration of the resultant single stranded pool was estimated by absorbance 
spectroscopy using a spectrophotometer (Nanodrop® ND-1000).  This pool was then 
used for the subsequent round of selection.  Negative selection was performed by 
incubating a representative, non-derivitized piece of cellulose with the pool for one hour 
and removing bound aptamers with the cellulose. 
To assess the non-specific binding of oligonucleotides to cellulose, we 5’ end 
labeled the pool with 33P as above, and approximately 30,000 counts per minute (cpm) of 
radiolabeled oligonucleotides in HMKN were incubated with a representative cellulose 
membrane benchtop for 1 hour.  The membrane was washed in an equal volume of 
HMKN five times.  The washes were combined and counted in a scintillation counter.  
Residual activity on the membrane was also determined by counting in a scintillation 





The single stranded DNA aptamer pool was first heated to 95°C for 5 minutes 
then allowed to refold at room temperature for 10 minutes in HMKN buffer. The pool 
was then incubated with PrPCWD prepared by ultracentrifugation as above in HMKN 
buffer for 30 minutes to 1 hour at room temperature.  The molar ratio of aptamer to 
PrPCWD in the first four rounds was 1:1 but was increased in some later rounds to 10:1 to 
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provide more competition between binding species.  The binding reaction was then 
placed in a 25 kDa molecular weight cut off dialysis membrane and suspended in an 
electroelution device (BioRad model 422 electroeluter).  The upper and lower chambers 
of the electroelution device were filled with HMKN buffer, and current applied (10 mA 
for first 8 rounds, then 70 mA for rounds 9-15) for 1 hour.  The suspension inside the 
dialysis membrane was then placed in a 1.5 mL microcentrifuge tube and used as the 
template for amplification of bound oligonucleotides.  PCR amplification was performed 
with differential primers (as noted above) such that the anti-sense strand contained a non-
extendable 20mer poly-adenine.  The amplification reaction was then separated on 
denaturing 20% urea polyacrylamide gels, the band containing the sense strand was cut 
out of the gel, diced and placed in double distilled water.  The gel suspension was 
incubated overnight to allow diffusion of oligonucleotides out of the gel and centrifuged 
at 14,000g for 1 minute to pellet the acrylamide.  The supernatant was recovered and the 
volume was reduced by extraction with butanol several times until the volume was below 
100 uL.  The oligonucleotides were then ethanol precipitated, recovered in HMKN 
buffer, and concentration was estimated using absorbance spectophotometry.  This pool 
was then used for the next round of SELEX. 
 
Negative selection 
A commercially available recombinant prion protein (rPrP, Prionics AG) was 
biotinylated using a commercially available kit (EZ-Link® Sulfo-NHS-Biotinylation Kit, 
Pierce).  Equimolar amounts of oligonucleotides and biotin-rPrP were incubated at room 
temperature for 1 hour in HMKN buffer.  The biotin-rPrP and bound oligonucleotides 
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were removed by adding streptavidin coated paramagnetic beads (Dynal Dynabeads® 
M270, Invitrogen), and the amount of oligonucleotides remaining in the supernatant was 
estimated by absorbance spectroscopy. 
 
Evaluation of current strength 
To assess the ability of different currents to induce the electrophorectic removal 
of unbound oligonucleotides from the dialysis membrane, we 5’ end labeled a pool of 
oligonucleotides as outlined above and placed 300,000 cpm (approximately 5 pmol) in 
HMKN inside a 25 kDa MWCO dialysis membrane. We then put the membrane in the 
electroelution apparatus and applied two different current strengths (10 mA and 70 mA) 
for 1 hour.  The fluid inside the dialysis membrane was recovered and placed in 
scintillation fluid for determination of cpm.  Aliquots of the combined upper and lower 
chambers were placed in scintillation fluid and the total cpm was calculated.  The 
electroelution device contains a membrane separating the upper and lower chambers and 
this membrane was cut out of the device and placed in scintillation fluid for cpm 
determination.  
 
Targeted epitope SELEX 
Two motifs of the prion protein represented by amino acids 89-112  and 136-158 
of the mouse (90-113 and 137-159 elk) prion protein were independently grafted to 
replace the heavy chain complementarity-determining region 3 of monoclonal antibody 
b12 and were a kind gift of Dr. R. Anthony Williamson [253].  MAb 90-113 (MAb A), 
MAb 137-159 (MAb B), and b12 were immobilized onto a gel substrate using a 
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commercially available kit (ProFound Co-Immunoprecipitation Kit, Pierce).  Coupling 
efficiency was estimated by measuring residual protein by BCA assay.  Prior to 
incubation with aptamer pools, the aptamer pools were heated to 95°C for 5 minutes and 
allowed to cool to room temperature for 10 minutes.  The single-stranded DNA aptamer 
pools were then incubated with equimolar amounts of antibody b12 coupled to gel (for 
negative selection) in HMKN for one hour with constant agitation at room temperature.  
The supernatant containing unbound aptamers was then separated from the antibody 
utilizing Handee™ Spin Cup columns provided with the kit and concentration of single-
stranded DNA oligonucleotides was estimated by absorbance spectophotometry.  This 
negative selection was performed for rounds 1, 2, 13, and 14.  For positive selection, the 
pools were incubated with MAb A or MAb B (equimolar amounts rounds 3-12, 2:1 
aptamer:target rounds 15-18, 10:1 aptamer:target rounds 19-20) in HMKN for one hour 
at room temperature.  The supernatant was removed using the columns as above, the 
bound aptamers were washed three times with HMKN, the retained antibody with bound 
aptamers were recovered and used as a template for PCR amplification using a 
biotinylated anti-sense primer.  The PCR reaction was then bound to streptavidin coated 
paramagnetic beads, washed, heated, flash-cooled, and single-stranded sense strands 
recovered as noted above.  The concentration of single stranded DNA oligonucleotides 
were then estimated by absorbance spectrophotometry, and this pool used for the next 
round of selection. 
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Cloning and Sequencing 
In order to assess the loss of sequence complexity (number of different sequences) 
in the pool, aliquots of the pool were amplified and placed into a cloning vector that was 
then used to transform chemically competent E. coli with a commercially available kit 
(TOPO-TA Cloning Kit, Invitrogen).  Successful transformants were identified by 
blue/white screening, picking white colonies that represented an interruption in the LacZ 
gene of the plasmid.  Individual colonies were selected and grown in Luria broth for 
plasmid purification.  Plasmid purification was accomplished using a commercially 
available kit (FastPlasmid™ Mini, Eppendorf, or PureLink™ Quick Miniprep Kit, 
Invitrogen).  These plasmids were sequenced by the Oklahoma State University 
Recombinant DNA/Protein Rescource Facility for sequencing.  Analysis of sequence 
alignments and evolutionary relationships was performed with Vector NTI Advance 10 
software from Invitrogen. 
 
Binding Assays 
Assessment of binding was performed using both pools of aptamers and using 
selected individual sequences.  Pool binding was performed after a number of rounds of 
SELEX to assess binding of the pool to PrPCWDand rPrP as compared to a negative 
control target (BSA).  Binding of individual sequences was assessed after the pools were 




Two-fold serial dilutions of PrPCWD, rPrP, and BSA (negative control) ranging from 20 
pmol to 0.625 pmol were immobilized on nitrocellulose using a Minifold® Dot Blot 
apparatus (Whatman).  The blot was blocked with 5% casein with 50 ng/mL tRNA for 1 
hour, washed five times with Tris buffered saline with 0.05% Tween-20 (TTBS), and 
rinsed twice in binding buffer (HMKN).  Probing of targets with radiolabeled pools of 
oligonucleotides was performed by incubating 5 pmol of (previously heat denatured and 
refolded in HMKN) radiolabeled pool in blocking buffer (with tRNA as above) with the 
blot for one hour with agitation.  The blots were rinsed three times with HMKN and 
exposed to radiographic film overnight at -70° C. 
 
Pull-down assay 
To assess the binding of aptamers to targets in solution, we adopted a strategy similar to 
that described by Rhie et al. [220] that utilizes Strataclean™ resin (Stratagene) that 
specifically pulls down proteins and molecules bound to proteins via a simple 
centrifugation step.  5' end labeled aptamers were heat denatured and allowed to refold in 
HMKN as previously described.  Each aptamer, labeled with 105 cpm 33P, was added to 
PrPCWD, rPrP (Prionics AG), and bovine serum albumin (BSA, Sigma Aldrich) at final 
concentrations of 100nM, 250nM, and 500nM in 30 µL of HMKN.  The reaction was 
incubated at room temperature for 1 hour with constant agitation, and 3 µL of
Strataclean™ resin was added.  The resin was centrifuged, supernatant removed, and the 
resin rinsed twice more with 30 uL of HMKN.  All supernatants were combined and 
counted in a scintillation counter as un-bound aptamer.  The final rinsed pellet was 
resuspended in 90 µL HMKN and counted in a scintillation counter as bound aptamer. 
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Results and Discussion 
 
Polymerase chain reaction amplification of oligonucleotides 
Optimization of PCR parameters for amplification of very short, randomized 
sequences is complicated by non-specific annealing between templates and primers 
(template-template and primer-template).  The production of the specific, desired product 
is critical to the entire downstream experiment.  We tested a range of magnesium 
concentrations across a range of annealing temperatures and found that an annealing 
temperature of 62°C and 2.5mM Mg++ yielded specific products of the appropriate size 
(figure 3-2). The final optimized reaction mix was comprised of 0.5 mM each dNTP, 1 
µM each primer, 2.5 mM Mg++, and 2 units of Immolase (Bioline) in 1X Immobuffer.  
Immolase is a heat activated polymerase that requires a 7 minute activation step at 94°C.  
Following this, the cycling parameters consisted of thirty cycles at 62°C for 30 seconds, 
72°C for 30 seconds, and 94°C for 30 seconds.   
 
Purification of PrPCWD 
 
PTA precipitation preparation of PrPCWD 
Enrichment for PrPCWD was performed by the PTA precipitation and proteinase K 
digestion method as described by Wadsworth et al. [250].  We evaluated this preparation 
by SDS PAGE electrophoresis and Coomassie blue staining to assess the degree of 
purification.  Figure 3-3 shows that there are appropriate bands at approximately 28 kDa 
and that there is a great reduction in proteins as compared to crude brain homogenate.  
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Western blotting of this preparation showed a strong signal as compared to controls and 
confirmed the presence of PrPCWD in our source material (figure 3-4).   
The selection strategy we devised was intended to select binding aptamers with as 
little sample preparation as possible, thus we used this method to positively identify the 
source material as containing PrPCWD but not for target presentation due to the cleavage 
of the amino terminus of PrPCWD by proteinase K.   
 
Ultracentrifugation preparation of PrPCWD 
Enrichment for PrPCWD was performed by  ultracentrifugation as described by 
Bolton et al. [251].  Assessment of the preparation was performed by Western blotting in 
serial, two-fold dilutions to confirm that the prepared PrPCWD contained the full length, 
processed protein with all three glycoforms present (figure 3-5).  Figure 3-5 also shows 
that we recovered a significant portion of the signal by comparison to similar amounts of 
starting tissue equivalents.  The total protein concentration in this preparation was 1.6 
mg/mL as determined by BCA assay. 
 
Cellulose Immobilized Peptides SELEX 
Initial SELEX was performed using peptides immobilized on cellulose as a target 
for selection.  Assessment of pool amplification by agarose gel electrophoresis showed 
large smears of amplicons that were thought to be due to high levels of template present 
in the PCR reaction.  Subsequently, non-specific binding of single stranded 
oligonucleotides to cellulose was evaluated by 5' end labeling with 33P.  Figure 3-6 
summarizes the results of three repeated experiments and shows that approximately 13% 
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of the oligonucleotide pool was non-specifically absorbed to the filter.  These non-
specifically bound oligonucleotides could not be separated from peptide-specific binders 
and represented a significant barrier to selection of binding aptamers.  At about the same 
time, the specificity of the Y-Y-R epitope for PrPSC was called into question [254] due to 
the potential for many other tyrosine-arginine motifs to be present in diagnostic samples 
such as blood.  The original description of the use of this antibody described it as one that 
could precipitate PrPSC, but subsequent detection in this study was accomplished with 
other anti-prion antibodies that do not distinguish PrPSC from PrPC, making the claim of 
PrPSC specificity doubtful.  Because of the problems of non-specific binding to cellulose 




Our initial experiments using cellulose as an immobilization substrate illustrates 
the problem of inefficient partitioning in SELEX experiments.  If unbound 
oligonucleotides are not removed, they are carried through to the amplification step and 
can quickly dominate the selected pool if they are present at concentrations higher than 
binding species.  Another potential problem of target immobilization is that selected 
aptamers might require the presence of the immobilization substrate to recognize the 
target.  This could occur due to binding of the substrate by aptamer species or to changes 
induced in the target molecule by the substrate [255].   
We reasoned that an ideal SELEX method would be highly efficient at 
partitioning bound from unbound species and occur in the absence of an immobilization 
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substrate.  Therefore, we devised a strategy to partition bound from unbound 
oligonucleotides based upon elecrophoretic mobility and to present the target to the pool 
of aptamers in binding buffer, absent any immobilization substrate.  Electrophoresis is a 
well established method of separating molecules based upon their relative size and charge 
and has been used in gel-shift assays to demonstrate aptamer binding to target molecules 
[223].  We reasoned that aptamers bound to a target, such as PrPSC would migrate more 
slowly than free aptamers when placed in an electrical field and that bound aptamers 
would be trapped inside a dialysis membrane with a differential molecular weight cut off 
selected to retain the large target molecule but allow the smaller, unbound aptamer 
molecules to pass across the membrane.  A total of fifteen rounds of SELEX were 
performed using the electrodialysis strategy outlined in Table 2, which summarizes the 
rounds and targets utilized.  Increasing stringency was applied to the selection by 
decreasing the amount of target relative to the moles of oligonucleotide in the pool 
(rounds 7-8) and by decreasing the incubation time (rounds 11-15).  Sequencing and 
binding assays were performed on enriched pools after rounds 4, 8, and 15 to assess the 
loss of complexity in the pool and the affinity of the pool for PrPCWD or rPrP as compared 
to BSA (discussed below).  We were unable to demonstrate loss of sequence complexity 
by alignment of recovered sequences after rounds 4 and 8.  We also were unable to 
demonstrate any difference in pool binding after rounds 4 and 8 to either form of PrP as 
measured by dot blotting or pull-down assay as described in materials and methods.  
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Evaluation of current strength 
Due to the lack of binding and little loss of sequence complexity after rounds 4 
and 8, we suspected that the current strength might not be high enough to thoroughly 
drive non-binding aptamers out of the dialysis membrane.  Therefore, we placed end-
labeled 33P oligonucleotides without a target in the dialysis membrane, placed the 
membrane in the electroelution apparatus, and applied two different current strengths (10 
mA and 70 mA) for 1 hour.  As shown at figure 3-7, we found that the amount of 
radiolabeled oligonucleotides remaining in the dialysis membrane at 10 mA was 16% of 
total input whereas at 70 mA approximately 1% remained.  We subsequently performed 




To assess the progress of enrichment for binding species, we cloned and 
sequenced aliquots of the pools at rounds four, eight, and fifteen.  Enrichment is reflected 
by a loss of sequence diversity as the pool of random oligonucleotides is selected for 
binding to a particular target.  The sequences of aptamer pools were analyzed by 
alignment and phylodendritic tree construction using Align X (Vector NTI Advance 10 
software).  The overall tree for 20 sequences from round 15 of electrodialysis SELEX is 
shown at Figure 3-8, and shows that the sequences fall into three broad families.  This 
demonstrates that some enrichment has occurred, as one would expect that completely 
non-related sequences would show a much more diverse dendrogram.  Additionally, the 
alignment within these three families shows that significant consensus was conserved in 
families 1 and 3 (figures 3-9 and 3-10), although no sequences were identical. 
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Many SELEX experiments demonstrate enrichment for binding species by the 
presence of a few dominant sequences in the final pool which can represent up to 80% of 
sequences recovered [256-258].  The lack of sequence identity occurring in our pool after 
fifteen rounds of SELEX is perplexing and could have several causes.  There could be an 
underlying design error such as insufficient selection pressure applied, a lack of 
partitioning bound from unbound species resulting in significant carryover of random 
species, or lack of binding to the target resulting in amplification and carryover of 
random species.  Alternatively, our negative selection strategy employed in an attempt to 
select PrPCWD specific aptamers could result in complete removal of binding species 
periodically through the SELEX process, a problem that would be futher compounded by 
non-specific binding of prion protein to single stranded DNA.   
We compared the sequences of our prion aptamers to those selected by other 
investigators (figure 3-11) and found that aptamer 15-8 was 55.6% identical to aptamer 
60-1 selected by Sekiya et al. [221] and 48.7% identical to aptamer M3 selected by 
Proske et al. [219].  Aptamer 15-7 also had strong identity with previously published 
aptamers, showing 28.6% identity with aptamer SAF-131 published by Rhie et al. [220]. 
We proceeded to select candidate aptamers based upon the phylodendritic 
relationship and alignment evidence demonstrated.   Aptamer 15-7 and 15-8 were 
selected for analysis of binding.  The sequences of these aptamers are: 
• 15-7:  5'- CGG GAA GGT GGA GCC GAG ACC GTT GTC ATC -3'  




In addition to aptamer 15-7 and 15-8, a randomly generated sequence (5'- GAG 
TCT TGG TGA CGT GCG TTG AGA TAC GCG -3' - scrambled aptamer) was also 
purchased for use as a control.  All three aptamers were 5' end labeled as described and 
incubated with three different concentrations of target molecules.  The bound and 
unbound fractions were determined by scintillation counting as described.  Figures 3-12 
through 3-14 show the comparisons of binding of different targets with each aptamer.   
Statistical analysis of data was performed using JMP 6.0.0 from SAS and multiple 
means comparison for each aptamer at each concentration of target showed that binding 
of aptamer 15-8 was significantly different (p < 0.05) for both PrPCWD and rPrP compared 
to binding of BSA (negative control) at all concentrations.  The binding of aptamer 15-8 
was not significantly different between PrPCWD or rPrP at any concentration analyzed 
which could be due to binding to a commonly presented epitope on each target.  The 
binding of aptamer 15-7 was significantly different (p < 0.05) for rPrP compared to 
PrPCWD at concentrations of 250nM and 500nM, but was not significantly different when 
compared to BSA at any concentration.  The binding of scrambled aptamer to all targets 
at all concentrations was not significantly different (p <0.05).   
To compare the level of binding to a specific target (for example, the binding of 
aptamer 15-8 and 15-7 to CWD) would require a method to normalize the amounts of 
total bound activity in each experiment.  We therefore included a control that would 
allow us to make such comparisons using E. coli single stranded DNA binding protein 
(SSB) [259].  This allowed calculation of percent specific binding using the equation:  
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The results of these calculations are shown graphically at figures 3-15 and 3-16 
and show that the binding of aptamer 15-8 is two to four times higher for PrPCWD than for 
SSB but the binding of aptamer 15-7 to CWD is less than the binding to SSB.  Similarly, 
the binding of aptaper 15-8 to rPrP was also higher than the binding to SSB whereas the 
binding of aptamer 15-7 was lower at all concentrations of target analyzed.  As expected, 
the binding of scrambled aptamer to either CWD or rPrP was much lower than binding to 
SSB except at the lowest concentration of rPrP (100nM), which is probably a spurious 
result but might be a reflection of some studies which show that rPrP binds to nucleic 
acids [231].  
 
Targeted epitope SELEX 
In an attempt to direct selection of aptamers that specifically bind to PrPCWD, we 
performed SELEX using motif grafted antibodies as targets for selection as described in 
materials and methods.  As described by Moroncini et al., these antibodies were 
constructed by replacing the coding sequence of the extended chain complementarity-
determining region 3 of monoclonal antibody b12 (a recombinant IgG developed against 
human immunodeficiency virus-1) with peptide sequences representing amino acid 
residues 90-113 (termed MAbA in this study) and 137-159 (termed MAbB in this study) 
of the elk prion protein sequence [253].  These sequences contain residues thought to be 
% specific binding = (cpm bound to target – cpm bound to BSA / cpm bound to SSB – cpm bound to BSA) X 100 
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important for the interaction between PrPC and PrPSC as evidenced by inhibition of prion 
propagation by Fab fragments reacting to regions in this region [260, 261], antibodies 
recognizing this segment [262, 263], and by synthetic PrP peptides spanning this region 
[62, 264].  We reasoned that since these regions are important for interaction between the 
two isoforms of PrP, epitopes within these regions might be differentially solvent 
exposed and thus aptamers that bind to these regions might differentially bind to one 
isoform or the other.  Table 3 summarizes the rounds and targets used in this strategy.  In 
an attempt to reduce non-specific binding to either the immunoglobulin backbone or the 
immobilization substrate, we performed negative selection with immobilized antibody 
b12.   
 
Sequencing 
We cloned and sequenced aliquots from each pool selected with MAbA or MAbB 
after round 12 and were unable to demonstrate loss of sequence diversity in either pool.  
Therefore, we performed an additional eight rounds of SELEX with each target and 
progressively increased the stringency of binding reactions by increasing the 
concentration of aptamer relative to target.  This theoretically provides a level of 
competition such that the best binding species could displace species with lower binding 
affinity.  As with the electrodialysis strategy, we compared the sequences recovered from 
round 20 for each target by phylodendritic tree construction and alignment using Align X. 
Figure 3-17 shows the phylodendritic tree of sequences recovered after selection 
with MAb A.  There are three major families, and the sequence of aptamer A15 is present 
in three copies, representing 15% of all sequences.  The sequence of aptamer A11 is 
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present in two copies, or 10% of all sequences.  Additionally, aptamer A15 shows a 
30.8% identity to the aptamer sequence published by Weiss et al. [218] (figure 3-18) and 
aptamer A11 shows strong identity to RM-312 [233] (figure 3-19) and SAF-131 [220] 
(figure 3-20).  The phylodendritic tree of sequences recovered after selection with MAb 
B is shown at figure 3-21.  There are five major families with no dominant sequences 
identified, but aptamer B55 shares a series of motifs with aptamer A15 (figure 3-22). 
Aptamers A15, A11, and B55 were selected for analysis of binding.  The 
sequence of these aptamers is: 
• A15:  5' - TGC AGG TAT GGG GTA TCG CTC CTC CCC TAA - 3' 
• A11:  5' – CTC CTA AAG CAC GGG GCC GTA AGC TGA TAG - 3' 
• B55:  5'- GCT TCA CCG ACA GAG GTG AGG TAC GCT CAC - 3' 
 
Binding 
Binding of aptamers A15, A11, and B55 to targets were measured by scintillation 
counting of bound, radiolabeled aptamers to the targets similar to that described for 
electrodialysis SELEX.  We measured the binding to a wider range of target 
concentrations (10nM to 500nM) and also included the target monoclonal antibody 
appropriate for each aptamer.  The same scrambled aptamer as used for electrodialysis 
binding was labeled and included as a control.  Figures 3-23 through 3-26 show the 
comparisons of binding of different targets with each aptamer.   
Statistical analysis of data was performed using JMP 6.0.0 from SAS and multiple 
means comparison for each aptamer at each concentration of target showed that binding 
of aptamer A15 was significantly different (p < 0.05) for PrPCWD and MAbA compared to 
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binding of BSA (negative control) at all concentrations except 100 nM (for PrPCWD – see 
table 3-4).  The binding of apatmer A15 to rPrP was not significantly different from the 
binding to BSA except at 25 nM and 50 nM.  The binding of aptamer A11 was 
significantly different between PrPCWD and BSA at all concentrations above 33nM, and 
the binding of this aptamer to rPrP was significantly different from BSA at target 
concentrations above 250nM (table 3-5).  Aptamer B55 was shown to bind to PrPCWD at 
significantly higher levels than BSA at all target concentrations except 10 nM and 500nM 
and bound to rPrP at significant levels as compared to BSA (table 3-6) at concentrations 
of 250nM and 500nM.  
As with the aptamers selected by electrodialysis, we calculated the specific 
binding of each aptamer to PrPCWD and to rPrP as a percentage of binding measured for 
each aptamer to SSB.  The results of these calculations are shown graphically at figures 
3-27 and 3-26 and show that the binding of aptamer A15 to PrPCWD was 20 to 80% of that 
measured for SSB whereas the binding of this aptamer to rPrP was less than 40% of that 
measured for SSB at all concentrations.  The binding of aptamer A11 to PrPCWD and rPrP 
was approximately 20 to 80% of SSB, and the binding of aptamer B55 was generally 30 




In this study, we have attempted to select PrPCWD specific aptamers to be used as 
molecular probes in diagnostic assay development.  To achieve this, we have developed 
two novel SELEX methods we have termed electrodialysis SELEX and targeted epitope 
SELEX.  We have used electrodialysis SELEX to select an aptamer (15-8) that binds to 
both isoforms of PrP as shown by comparison to binding a negative control protein 
(BSA).  Aptamer 15-8 also binds to PrPCWD and rPrP at levels higher than SSB as shown 
by percent specific binding.  The apparent lack of significant differential binding to 
PrPCWD as compared to PrPC is similar to the findings of other investigators, indicating 
that the full length prion protein in either isoform may be a poor target for selection of 
conformation-specific aptamers.  Successful selection of PrPCWD-specific aptamers may 
depend upon presentation of differentially exposed epitopes as selection targets in the 
absence of confounding common regions of the two isoforms of prion protein that may 
bind nucleic acids with high affinity.   
The motif grafted monoclonal antibodies used in this study represent such 
potential targets.  Aptamer A15 was shown to consistently bind to PrPCWD at significantly 
higher levels compared to BSA and the specific binding of this aptamer indicate that it 
may has some specificity for PrPCWD (figure 3-29).  The binding of aptamers A11 and 
B55 to PrPCWD and rPrP were not as consistently different from BSA and the specific 
binding calculated using SSB were also not consistently different.  For example, aptamer 
B55 specifically binds to PrPCWD at lower concentrations but specifically binds to rPrP at 
higher concentrations (see figure 3-30). 
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In summary, we have identified a total of five potential aptamers that can bind to 
prion protein.  Of these, aptamer A15 binds toPrPCWD at higher levels than rPrP, and 
aptamer 15-8 binds to both PrPCWD and rPrP at higher affinity levels than SSB.  Studies 
of the kinetics of the binding of each of these aptamers are warranted to identify and 
further clarify the potential of any of these aptamers as specific probes for PrPCWD.
Although we attempted several strategies aimed at selecting a specific aptamer 
that could recognize PrPCWD and differentiate it from PrPC, we were only moderately 
successful.  Selection of a specific aptamer that can bind to the abnormal, disease 
associated isoform of prion protein has proven difficult for many investigators.  As 
shown in table 3-7, there have been at least five published studies describing the selection 
of aptamers to prion protein and only two of theseclaim to have selected aptamers that 
preferentially bind PrPSC, and neither of these has been developed into a diagnostic 
reagent.  This may indicate that selection of a specific aptamer for the disease associated 
form of prion protein will require alternative approaches of selection not yet considered.  
The two isoforms of prion protein should theoretically be distinguishable by aptamers, as 
aptamers have been shown to distinguish even different enantiomers of the same 
molecule [265-267].  Although the exact tertiary structure of PrPSC is unknown, it is 
known that the two isoforms differ in secondary and tertiary structure which should 
present at least one differential target for selection.  Therefore, the difficulty in selecting a 
specific aptamer for PrPSC (or PrPCWD) is unlikely due to the inability of aptamers to 
resolve differences from PrPC. Potential factors that could account for the lack of 
selection of a specific aptamer include nonspecific nucleic acid binding properties of PrP 
and insolubility of PrPSC in selection buffers.  The field of aptamer selection is growing 
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increasingly sophisticated and selection of a specific aptamer for PrPSC may yet be 




1. Prusiner, S.B., Novel proteinaceous infectious particles cause scrapie. Science, 
1982. 216(4542): p. 136-44. 
2. Horiuchi, M. and B. Caughey, Prion protein interconversions and the 
transmissible spongiform encephalopathies. Structure, 1999. 7(10): p. R231-40. 
3. O'Rourke, K.I., et al., Preclinical diagnosis of scrapie by immunohistochemistry 
of third eyelid lymphoid tissue. J Clin Microbiol, 2000. 38(9): p. 3254-9. 
4. Tuerk, C. and L. Gold, Systematic evolution of ligands by exponential 
enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990. 
249(4968): p. 505-10. 
5. Weiss, S., et al., RNA aptamers specifically interact with the prion protein PrP. J
Virol, 1997. 71(11): p. 8790-7. 
6. Proske, D., et al., Prion-protein-specific aptamer reduces PrPSc formation. 
Chembiochem, 2002. 3(8): p. 717-25. 
7. Rhie, A., et al., Characterization of 2'-fluoro-RNA aptamers that bind 
preferentially to disease-associated conformations of prion protein and inhibit 
conversion. J Biol Chem, 2003. 278(41): p. 39697-705. 
8. Sekiya, S., et al., Characterization and application of a novel RNA aptamer 
against the mouse prion protein. J Biochem (Tokyo), 2006. 139(3): p. 383-90. 
9. Sekiya, S., et al., In vitro selection of RNA aptamers against cellular and 
abnormal isoform of mouse prion protein. Nucleic Acids Symp Ser (Oxf), 2005(49): p. 
361-362. 
10. Takemura, K., et al., DNA aptamers that bind to PrP(C) and not PrP(Sc) show 
sequence and structure specificity. Exp Biol Med (Maywood), 2006. 231(2): p. 204-14. 
11. Adler, V., et al., Small, highly structured RNAs participate in the conversion of 
human recombinant PrP(Sen) to PrP(Res) in vitro. J Mol Biol, 2003. 332(1): p. 47-57. 
12. Cordeiro, Y., et al., DNA converts cellular prion protein into the beta-sheet 
conformation and inhibits prion peptide aggregation. J Biol Chem, 2001. 276(52): p. 
49400-9. 
13. Deleault, N.R., R.W. Lucassen, and S. Supattapone, RNA molecules stimulate 
prion protein conversion. Nature, 2003. 425(6959): p. 717-20. 
14. Nandi, P.K. and J.C. Nicole, Nucleic acid and prion protein interaction produces 
spherical amyloids which can function in vivo as coats of spongiform encephalopathy 
agent. J Mol Biol, 2004. 344(3): p. 827-37. 
15. Nandi, P.K., et al., DNA-induced partial unfolding of prion protein leads to its 
polymerisation to amyloid. J Mol Biol, 2002. 322(1): p. 153-61. 
106
16. Nandi, P.K. and P.Y. Sizaret, Murine recombinant prion protein induces ordered 
aggregation of linear nucleic acids to condensed globular structures. Arch Virol, 2001. 
146(2): p. 327-45. 
17. Nandi, P.K. and E. Leclerc, Polymerization of murine recombinant prion protein 
in nucleic acid solution. Arch Virol, 1999. 144(9): p. 1751-63. 
18. Mercey, R., et al., Fast, reversible interaction of prion protein with RNA aptamers 
containing specific sequence patterns. Arch Virol, 2006. 151(11): p. 2197-214. 
19. Paramithiotis, E., et al., A prion protein epitope selective for the pathologically 
misfolded conformation. Nat Med, 2003. 9(7): p. 893-9. 
20. Solforosi, L., et al., Cross-linking cellular prion protein triggers neuronal 
apoptosis in vivo. Science, 2004. 303(5663): p. 1514-6. 
21. Moroncini, G., et al., Pathologic prion protein is specifically recognized in situ by 
a novel PrP conformational antibody. Neurobiol Dis, 2006. 23(3): p. 717-24. 
22. Wadsworth, J.D., et al., Tissue distribution of protease resistant prion protein in 
variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet, 
2001. 358(9277): p. 171-80. 
23. Bolton, D.C., et al., Isolation and structural studies of the intact scrapie agent 
protein. Arch Biochem Biophys, 1987. 258(2): p. 579-90. 
24. Esposito, D.L., et al., Optimized PCR labeling in mutational and microsatellite 
analysis. Clin Chem, 1998. 44(7): p. 1381-7. 
25. Moroncini, G., et al., Motif-grafted antibodies containing the replicative interface 
of cellular PrP are specific for PrPSc. Proc Natl Acad Sci U S A, 2004. 101(28): p. 
10404-9. 
26. Gorochov, G. and J.P. Deslys, Properties of a disease-specific prion probe. Nat 
Med, 2004. 10(1): p. 11; author reply 11-2. 
27. Fitzwater, T. and B. Polisky, A SELEX primer. Methods Enzymol, 1996. 267: p. 
275-301. 
28. Mallikaratchy, P., et al., Selection of DNA ligands for protein kinase C-delta. 
Chem Commun (Camb), 2006(30): p. 3229-31. 
29. Mendonsa, S.D. and M.T. Bowser, In vitro selection of high-affinity DNA ligands 
for human IgE using capillary electrophoresis. Anal Chem, 2004. 76(18): p. 5387-92. 
30. Vianini, E., M. Palumbo, and B. Gatto, In vitro selection of DNA aptamers that 
bind L-tyrosinamide. Bioorg Med Chem, 2001. 9(10): p. 2543-8. 
31. Krauss, G., et al., Escherichia coli single-strand deoxyribonucleic acid binding 
protein: stability, specificity, and kinetics of complexes with oligonucleotides and 
deoxyribonucleic acid. Biochemistry, 1981. 20(18): p. 5346-52. 
32. Williamson, R.A., et al., Mapping the prion protein using recombinant 
antibodies. J Virol, 1998. 72(11): p. 9413-8. 
33. Peretz, D., et al., Antibodies inhibit prion propagation and clear cell cultures of 
prion infectivity. Nature, 2001. 412(6848): p. 739-43. 
34. Heppner, F.L., et al., Prevention of scrapie pathogenesis by transgenic expression 
of anti-prion protein antibodies. Science, 2001. 294(5540): p. 178-82. 
35. Enari, M., E. Flechsig, and C. Weissmann, Scrapie prion protein accumulation by 
scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. 
Proc Natl Acad Sci U S A, 2001. 98(16): p. 9295-9. 
107
36. Chabry, J., et al., Species-independent inhibition of abnormal prion protein (PrP) 
formation by a peptide containing a conserved PrP sequence. J Virol, 1999. 73(8): p. 
6245-50. 
37. Chabry, J., B. Caughey, and B. Chesebro, Specific inhibition of in vitro formation 
of protease-resistant prion protein by synthetic peptides. J Biol Chem, 1998. 273(21): p. 
13203-7. 
38. Shoji, A., et al., Modified DNA aptamer that binds the (R)-isomer of a 
thalidomide derivative with high enantioselectivity. J Am Chem Soc, 2007. 129(5): p. 
1456-64. 
39. Ruta, J., et al., Chiral resolution of histidine using an anti-D-histidine L-RNA 
aptamer microbore column. J Chromatogr B Analyt Technol Biomed Life Sci, 2007. 
845(2): p. 186-90. 
40. Williams, K.P., et al., Bioactive and nuclease-resistant L-DNA ligand of 
















Figure 3-1 Illustration of SELEX strategy. 
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Figure 3-2.  Examples of PCR optimization.  A. Optimization at 60 °C annealing temperature: 4.5% 
agarose gel with PCR reactions containing different concentrations of Mg++.  Asterisk 
marks 75 bp band, arrow indicates undesirable, high molecular weight species.   Lane 1 - 
HyperLadder V (Bioline).  Lanes 2 – 8 - Mg++ gradient 0.5, 1, 2, 2.5, 3, 4, 5 mM Mg++.   
B. 4.5% Agarose gel showing six separate PCR reactions at optimized conditions.  
Asterix indicates 75 bp band. Lane 1- HyperLadder V.  Lanes 2-7 Separate PCR 
reactions performed at optimized conditions (2.5 mM Mg++, 62°C annealing 
temperature).  C. Example of denaturing urea, 20% PAGE gel loaded with PCR 
reactions performed with anti-sense primer containing a non-extendable, twenty 
nucleotide poly-adenosine ‘tail’.  Asterix indicates the band containing single stranded 






Figure 3-3.  Assessment of PTA precipitation preparation of PrPCWD by SDS PAGE and Coomassie 
blue staining.  Lane 1 – Protein Standards.  Lane 2 – Negative Elk brain prepared by 
PTA precipitation and proteinase K digestion. Lanes 3-5 – Serial 2 fold dilutions of 
positive Elk brain used as source of PrPCWD prepared by PTA precipitation and 
proteinase K digestion. Lanes 6-8 – Serial two-fold dilutions of clarified brain 
homogenates from positive elk brain. Lanes 9-10 PTA precipitated samples of scrapie 
infected sheep brain (kindly provided by Dr. Katherine O’Rourke).  All samples were 
loaded at 2 mg equivalents (except for diluted samples), separated by electophoresis on 
15% polyacrylamide gels, and stained with Coomassie blue.  Approximate molecular 
weights at left in kDa. 
 








Figure 3-4.  Western blot of PrPCWD prepared by PTA precipitation.  Lane 1 – 3 µg rPrP.  Lane 2 – 
known positive elk used as control.  Lane 3 – known scrapie positive sheep used as 
control.  Lanes 4 and 6  – blank.  Lanes 5 and 7 – Sample prepared with brain material 
used as source of PrPCWD in this study.  Approximately 3 µg of rPrP and 2mg 
equivalents of starting material were loaded.  Samples were separated by electrophoresis 
on a 15% polyacrylamide gel, transfered to nitrocellulose, and probed with MAb 
F89/160.1.5.   A horseradish peroxidase conjugated goat anti-mouse antibody was used as 
the secondary antibody and enhanced chemiluminescent substrate (Pierce) was used for 
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Figure 3-5.  Western blot of serial two-fold dilutions of PrPCWD prepared by ultracentrifugation.  
Lanes 1-5: serial 2 fold dilutions of preparation.  Lane 6:  clarified brain homogenate of 
starting material.  The amount of material loaded into lanes 1 and 6 represents the 
equivalent of approximately 2 mg of starting material.  The preparations separated by 
electrophoresis on a 15% polyacrylamide gel, transferred to nitrocellulose, and probed 
with MAb F89/160.1.5.   A horseradish peroxidase conjugated goat anti-mouse antibody 
was used as the secondary antibody and enhanced chemiluminescent substrate (Pierce) 
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% remaining on filter
Figure 3-6.  Non-specific binding of radiolabeled oligonucleotides to cellulose membranes.  
Approximately 30,000 cpm of end labeled oligonucleotides were incubated with a 
dervitized cellulose membrane in HMKN for one hour, extensively washed, and the 





























Figure 3-7.  Evaluation of the ability of two different current strengths to displace unbound aptamers 
from the dialysis membrane in electrodialysis SELEX.  End labeled oligonucleotides were 
placed in the dialysis membrane and different currents were applied for one hour.  The 
amount of radiolabeled oligonucleotides relative to the input were determined for the 
dialysis membrane, withinthe electrophoresis buffer, and elution trap were determined 






















Figure 3-8.  Phylodendritic tree showing relationships of 20 aptamer sequences after 15 rounds of 
















C TG AG T TAC C TAC TGTConsensus (1)  













C GA T TATG CTGTG T G TACConsensus (1)  











A GG GG CG GA G TG GGTGCGCConsensus (1)  





















15-8 PrP bound 
15-8 BSA bound 
Figure 3-12.  Binding of radiolabeled aptamer 15-8 to different concentrations of target molecules as 
measured by total scintilation counts pulled down.  100,000 cpm of labeled aptamer was 
incubated with indicated concentration of target for one hour in HMKN buffer.  The 
protein targets and bound oligonucleotides were separated from unbound 
oligonucleotides by the addition of Strataclean resin.  The resin was washed twice with 
HMKN and placed in scintillation fluid for scintillation counting. Binding of 15-8 to 
CWD and rPrP was significantly different from BSA as measured by Tukey-Kramer 


















Figure 3-13.  Binding of radiolabeled aptamer 15-7 to different concentrations of target molecules as 
measured by total scintilation counts pulled down.  100,000 cpm of labeled aptamer was 
incubated with indicated concentration of target for one hour in HMKN buffer.  The 
protein targets and bound oligonucleotides were separated from unbound 
oligonucleotides by the addition of Strataclean resin.  The resin was washed twice with 
HMKN and placed in scintillation fluid for scintillation counting.  Binding of 15-7 to 
CWD or rPrP was not signicantly different from BSA as measured by Tukey-Kramer 
HSD analysis (p < 0.05), but 15-7 binding to rPrP was significantly different than 



















Figure 3-14.  Binding of radiolabeled scrambled aptamer to different concentrations of target 
molecules as measured by total scintilation counts pulled down.  100,000 cpm of labeled 
aptamer was incubated with indicated concentration of target for one hour in HMKN 
buffer.  The protein targets and bound oligonucleotides were separated from unbound 
oligonucleotides by the addition of Strataclean resin.  The resin was washed twice with 
HMKN and placed in scintillation fluid for scintillation counting.  Binding of scrambled 




Figure 3-15.  Specific binding of selected aptamers to PrPCWD as percent of bound to SSB minus 
bound to BSA.  Radiolabeled aptamers were incubated with the indicated 
concentrations of PrPCWD, BSA, and SSB for one hour in HMKN.  The protein targets 
and bound oligonucleotides were separated from unbound oligonucleotides by the 
addition of Strataclean resin.  The resin was washed twice with HMKN and placed in 
scintillation fluid for scintillation counting.  Specific binding was calculated by 
subtracting the counts bound to BSA from the counts bound to PrPCWD and SSB, then 
dividing the difference of PrPCWD by the difference of SSB. 






























Figure 3-16.  Specific binding of selected aptamers to rPrP as percent of bound to SSB minus bound 
to BSA.  Radiolabeled aptamers were incubated with the indicated concentrations of 
rPrP, BSA, and SSB for one hour in HMKN.  The protein targets and bound 
oligonucleotides were separated from unbound oligonucleotides by the addition of 
Strataclean resin.  The resin was washed twice with HMKN and placed in scintillation 
fluid for scintillation counting.  Specific binding was calculated by subtracting the 
counts bound to BSA from the counts bound to rPrP and SSB, then dividing the 























Figure 3-17.  Phylodendritic tree showing relationships of 20 aptamer sequences after 20 rounds of 
selection by targeted epitope SELEX with MAbA.  Three major families are present as 
indicated by the brackets.  The species represented by A8 comprising 15% of 








TG GG ATGGGG A GConsensus (1)  
Figure 3-18.  Individual sequence alignments of aptamers A15 and the aptamer selected by Weiss et. 
al showing 30.8% identity. 
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1 6410 20 30 40 50(1)
---------------CTCCTAAAGCACGGGGCCGTAAGCTGATAG-------------------A11 (1)
TCAAGACGTCGGGGATTGGCAAACCCCGTTTCCTTGAGC-GACCCCCTGTTACTCGGCGGATCCRM312 (1)
T AAA C CG CC T AGC GAConsensus (1)  
Figure 3-19.   Individual sequence alignments of aptamers A11 and RM312 showing 23.4% identity. 
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1 5110 20 30 40(1)
---------------------CTCCTAAAGCACGGGGCCGTAAGCTGATAGA11 (1)
GCTGACCACCGCCAACGCAACCTCCAATGACTTGGATCACCTAGACGAT--SAF-131 (1)
CTCC A C GG C AG GATConsensus (1)  




























Figure 3-21.  Phylodendritic tree showing relationships of 26 aptamer sequences after 20 rounds of 










CAG TG GGTA CGCTCConsensus (1)  























Figure 3-23.  Binding of radiolabled MAb A Aptamer A15 to different concentrations of target 
molecules as measured by total scintillation counts pulled down.  100,000 cpm of labled 
aptamer was incubated with indicated concentration of target for one hour in HMKN 
buffer.  The protein targets and bound aptamers were separated from unbound 
aptamers by the addition of Strataclean resin.  The resin was washed twice with HMKN 
and placed in scintillation fluid for scintillation counting.   
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Figure 3-24.  Binding of radiolabled MAb A Aptamer A11 to different concentrations of target 
molecules as measured by total scintillation counts pulled down.  100,000 cpm of labled 
aptamer was incubated with indicated concentration of target for one hour in HMKN 
buffer.  The protein targets and bound aptamers were separated from unbound 
aptamers by the addition of Strataclean resin.  The resin was washed twice with HMKN 
and placed in scintillation fluid for scintillation counting.   
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Figure 3-25.  Binding of radiolabled MAb b Aptamer B55 to different concentrations of target 
molecules as measured by total scintillation counts pulled down.  100,000 cpm of labled 
aptamer was incubated with indicated concentration of target for one hour in HMKN 
buffer.  The protein targets and bound aptamers were separated from unbound 
aptamers by the addition of Strataclean resin.  The resin was washed twice with HMKN 





















Figure 3-26.  Binding of radiolabeled scrambled aptamer to different concentrations of target 
molecules as measured by total scintilation counts pulled down.  100,000 cpm of labeled 
aptamer was incubated with indicated concentration of target for one hour in HMKN 
buffer.  The protein targets and bound oligonucleotides were separated from unbound 
oligonucleotides by the addition of Strataclean resin.  The resin was washed twice with 
HMKN and placed in scintillation fluid for scintillation counting. 
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Figure 3-27.  Specific binding of selected aptamers to PrPCWD as percent of bound to SSB minus 
bound to BSA.  Radiolabeled aptamers were incubated with the indicated 
concentrations of PrPCWD, BSA, and SSB for one hour in HMKN.  The protein targets 
and bound oligonucleotides were separated from unbound oligonucleotides by the 
addition of Strataclean resin.  The resin was washed twice with HMKN and placed in 
scintillation fluid for scintillation counting.  Specific binding was calculated by 
subtracting the counts bound to BSA from the counts bound to PrPCWD and SSB, then 
dividing the difference of PrPCWD by the difference of SSB. 
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Figure 3-28.  Specific binding of selected aptamers to rPrP as percent of bound to SSB minus bound 
to BSA.  Radiolabeled aptamers were incubated with the indicated concentrations of 
rPrP, BSA, and SSB for one hour in HMKN.  The protein targets and bound 
oligonucleotides were separated from unbound oligonucleotides by the addition of 
Strataclean resin.  The resin was washed twice with HMKN and placed in scintillation 
fluid for scintillation counting.  Specific binding was calculated by subtracting the 
counts bound to BSA from the counts bound to rPrP and SSB, then dividing the 
difference of rPrP by the difference of SSB. 
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Figure 3-29.  Specific binding of aptamerA15 to PrPCWD, rPrP, and MAbA as percent of bound to 
SSB minus bound to BSA.   
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Figure 3-30.  Specific binding of aptamerB55 to PrPCWD, rPrP, and MAbB as percent of bound to 
SSB minus bound to BSA. 
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Strategy Number Target presentation Separation Method Assessment 
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Table 3-1.  Outline of SELEX strategies used for selection of an aptamer that specifically recognizes 
PrPCWD 
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1-4 1 hour PrPCWD 1:1 Positive Binding assay and sequencing 
5-6 1 hour recPrP 1:1 Negative  
7-8 1 hour PrPCWD 1:10 Positive Binding assay and sequencing 
9-10 1 hour recPrP 1:1 Negative  
11-15 30 minutes PrPCWD 1:1 Positive Binding assay and sequencing 
Table 3-2.  Outline of electrodialysis SELEX.  Negative selection was performed at rounds 5-6 and 
rounds 9-10 in an attempt to remove oligonucleotides that bind to PrPC.
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1-2 1 hour b12 1:1 Negative  
3-12 1 hour MAb A MAb B 1:1 Positive Sequencing 
13-14 1 hour b12 1:1 Negative 
15-18 1 hour MAb A MAb B 1:2 Positive  
19-20 1 hour MAb A MAb B 1:10 Positive Sequencing 
Table 3-3.  Outline of targeted epitope SELEX.  Negative selection was performed in rounds 1, 2, 13, 
and 14 to remove aptamers that bind to the gel substrate or areas of antibody b12 outside 
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Table 3-4.  Mean (µ) and standard deviation (σ) of aptamer A15 bound to targets as measured by 
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Table 3-5.  Mean (µ) and standard deviation (σ) of aptamer A11 bound to targets as measured by 
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Table 3-6.  Mean (µ) and standard deviation (σ) of aptamer B55 bound to targets as measured by 
scintillation counting (CPM).  Different letters across rows indicate significantly different 
(p<0.05) groups. 
144
Author/Date RNA/DNA Interaction site PrPSC specific? 
Weiss 1997 RNA 23-52 No 
Proske 2002 RNA 90-124 No 
Rhie 2003 RNA 23-110 >110 
No 
Yes 
Sekiya 2006 RNA 23-108 Possible 
Takemura 2006 DNA <90 No 
Table 3-7.  Summary of published studies to select aptamers to prion protein. 
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Chapter 4.  Development of a cell culture bioassay for detection and 





Chronic wasting disease (CWD) is a transmissible spongiform encephalopathy 
(TSE) that affects North American cervidae, including white-tailed deer, mule deer, 
Rocky Mountain elk, and moose.  TSEs are also known as prion diseases because it is 
believed that the underlying pathologic mechanism involves the misfolding of a normal 
cellular prion protein (PrPC) to an isoform (PrPSC) that is associated with disease.  PrPSC 
(either alone or with other unidentified molecules) can induce misfolding of more PrPC
by an unknown mechanism, and this characteristic is thought to confer its infectious 
properties.  All diagnostic assays rely upon identification of PrPSC in a sample for 
confirmation of TSEs, but quantification and characterization of infectivity requires the 
use of live animal bioassay.  Cell culture models of TSEs have been proposed as one way 
to circumvent bioassay and have been shown to rival bioassay in terms of sensitivity 
[240].  Cell culture models have also been used to study underlying molecular events 
involved in conversion, subcellular localization, understanding species barriers, and 
therapeutic drug screening.  In this study, we created a GFP:elk PrP expression construct 
for transient expression of the fusion protein in bovine lymphoma cell line BL3.1.  
Although we were not able to show expression at the cell surface using our final 
construct, we were able to show transient expression of a GFP:elkPrP fusion protein 
lacking the amino terminal signal peptide of PrP.  This fusion protein remained 
intracellular and seemed to be localized to a perinuclear cellular compartment. 
147
Introduction and background 
 
TSEs are a group of uniformly fatal neurodegenerative diseases that include 
bovine spongiform encephalopathy (BSE) in cattle, Creutzfeld-Jakob Disease (CJD) in 
humans, scrapie in sheep, and chronic wasting disease (CWD) in cervids.  These diseases 
are strongly associated with an abnormal isoform of a normal cellular protein, prion 
protein (PrPC).  PrPC is normally a membrane bound protein expressed on the cell 
surface; its function is not fully characterized, but it may play a role in protection from 
oxidative stress, copper binding, or even memory formation [54, 59, 268-270].  In the 
pathologic state, the normal PrPC changes from a state of high alpha helix content to a 
beta sheet rich, protease resistant form (PrPres or PrPSC).  The exact mechanism is not 
fully understood, but PrPSC can induce mis-folding of PrPC. This self-propagating, 
infectious nature was first proposed in 1982 by Stanley Prusiner and formed the basis of 
the prion hypothesis which described this novel infectious agent as being comprised 
solely of the misfolded protein, absent any nucleic acid [8].  While controversial and still 
not completely accepted by all investigators, this hypothesis has withstood scrutiny and 
gained acceptance in the last quarter century.  PrPSC is at least absolutely critical for 
infection, if not the sole infectious agent.  Transmission of infection is dependent upon 
expression of PrPC in the host, as prnP-/- null mice are resistant to infection [133].  
Additionally, the efficiency of conversion to PrPSC is greatly enhanced if the PrPC of the 
host matches the species of infectious agent, a characteristic which forms the basis of the 
species barrier. 
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CWD was first described in the late 1960’s in a group of captive mule deer in 
northeastern Colorado.  It was subsequently found in captive Rocky Mountain elk, then 
in wild species of mule deer, white-tailed deer, elk, and moose.  It has now been detected 
in at least sixteen states and provinces in North America.  This expanding range may be a 
reflection of an emerging disease, increased surveillance, or both [100].  In comparison to 
the other known TSE diseases, CWD-specific research has been very limited, and the 
threat to human health by CWD is not known [103, 271].  Since many deer and elk 
harvested are slaughtered and prepared in the absence of government inspection, the 
inclusion of potentially infectious material in food intended for human consumption 
might be more likely if this agent can cross the species barrier. 
The characterization of the prion protein gene (prnP) in mice [16] and hamsters 
[272] and the subsequent development of transgenic models for TSE disease has led to 
great strides in understanding basic prion biology, species barriers, transmission routes, 
and pathogenesis.   Prior to the advent of transgenic mice expressing heterologous PrPC,
prion infection had been successfully transmitted to mice, but the efficiency of 
transmission was very low [273].  This illustrates the general principle that TSE diseases 
show a preference for transmission to the species of origin or a closely related species.   
Animal models have been used for the characterization and quantification of 
infectivity in biological assays, and these bioassays are the most sensitive measure of 
prion infectivity.  Suspect material is inoculated intracerebrally and infectivity is 
measured based upon time of incubation or LD50 [274].  The use of cell culture methods 
to study TSE diseases has augmented animal model studies and allowed exploration of 
cellular trafficking of PrP [166, 275-282].  Klohn et al. have described a cell culture 
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based assay for mouse scrapie prion infectivity [245].  The sensitivity of this assay 
compared favorably to mouse bioassay and was ten times faster and much less expensive.  
A review of cell culture models lists nine neural cell lines and seven non-neural 
cell lines permissive to prion replication [246].  By far the most common cell line used in 
published studies is the persistently infected line N2a, a line infected with mouse-adapted 
Chandler strain of scrapie.  Many investigators are attempting to develop specific TSE 
agent permissive cultures, and this has resulted in a recent line of brain derived 
fibroblasts that are persistently infected with CWD [247].  Cell culture models of prion 
disease hold great promise for detection, characterization, and intervention studies of 
prion disease. 
The objective of this study was to develop a cell culture model for CWD prion 
propagation that can be used as a bioassay for detecting CWD in a diagnostic assay, for 
characterization of CWD infectivity, as a basic research tool, and as a potential 
therapeutic drug screening assay.  Our approach focused on bioengineering a bovine B-
lymphocyte cell (B-cell) line to surface express elk PrPC fused to green fluorescent 
protein (GFP) which could then be used as a cell culture bioassay for CWD prion 
propagation.   
Prion protein is a cell surface, glycosyl-phosphoinositol (GPI) anchored protein.  
It contains an amino terminal signal peptide that acts to direct the protein into the 
endoplasmic reticulum (ER) concurrent with translation.  This signal peptide is cleaved in 
the ER and the protein undergoes several other post-translational modifications, including 
the addition of asparagine-linked glycans, di-sufide bond formation between cysteine 
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residues 187 and 222, and the replacement of the carboxy-terminal GPI signal sequence 
with the GPI anchor.  
The introduction of green fluorescent protein fusion proteins has greatly 
facilitated intracellular trafficking and localization experiments for many proteins, 
including both PrPC and PrPSC.  [283-288].  Transfection and surface expression of green 
fluorescent protein fusions with prion proteins from other TSEs have been demonstrated 
previously [286, 288], and other investigators have shown that a GFP-PrP fusion protein 
can support prion replication [289]. 
We hypothesized that since the GPI anchor acts to localize associated proteins to 
lipid rafts on the plasma membrane [43],  expressed GFP-PrPC would be directed and 
anchored to the outer cell membrane by the GPI terminus of PrP, and would have a 
dispersed distribution on the B-cell surface.  We further hypothesized that interaction of 
these B-cells with infectious, mis-folded, protease resistant CWD prion (PrPCWD) would 
induce conversion of the dispersed GFP-PrPC to aggregated mis-folded GFP-PrPCWD that 
could be detected by confocal microscopy as aggregates of fluourescence on the B-cell 
surface.  
B-cells were chosen as the model cell line for CWD because there is evidence for 
their involvement in the propagation and spread of PrPCWD from the spleen and lymph 
nodes to the nervous system (Sigurdson et al 2002).  In general, TSEs are spread by 
ingestion of PrPSC, which is then absorbed from the gastrointestinal tract, picked up by 
antigen-presenting (APC) dendritic cells and transported to the spleen and lymph nodes.  
In the lymph node, follicular dendritic cells (FDCs) and B-cells have been shown to have 
strong PrPSC signals in double-label immunohistochemical staining studies [154], and 
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other authors have shown that these FDCs are concentrated in B-lymphocyte germinal 
centers and come into contact with B-cells [290, 291].  Thus, the proposed assay is 
biologically relevant and the fusion of a fluorescent marker protein should not be a 
barrier to conversion of PrPC to PrPCWD.
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Materials and methods 
Cell culture 
BL3.1 cells are bovine B lymphocytes (ATCC # CRL-2306) that are positive for 
bovine leukemia virus.  The cells were maintained in suspension in RPMI 1640 medium 
with 2 mM L-glutamine adjusted to 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM 
HEPES, and 1.0 mM sodium pyruvate with 10% fetal bovine serum at 37°C and 5% CO2.
The medium was renewed every 2-3 days as necessary to maintain cell concentrations 
between approximately 5 X 105 – 2 X 106 cells/mL. 
 
EGFP:PrP expression vector construction 
The coding sequence for amino acids 25-256 of the elk prion protein (the coding 
sequence of the entire protein C-terminal to the signal peptide) was amplified by PCR 
from an expression plasmid (kindly provided by Dr. Katherine O’Rourke USDA ARS, 
Pullman, WA) with primers containing restriction sites for XbaI (sense primer) and 
EcoRI (anti-sense primer).  The PCR product was purified by electrophoresis on a 2% 
agarose gel, recovered from the gel using a commercially available kit (Wizard® SV Gel 
and PCR Clean-Up System, Promega), and subjected to restriction digestion with XbaI
and EcoRI.  A GFP fusion vector (pEGFP-C1, BD Biosciences) was used to transform a 
dam- E. coli strain (SCS110 cells, Stratagene).  SCS110 cells were used because XbaI is 
sensitive to dam methylation at the restriction site.  The cells were incubated in Luria 
broth with 30 µg/mL kanamycin overnight.  The plasmid was purified using a 
commercially available kit (PureLink™ Quick Miniprep Kit, Invitrogen), subjected to 
restriction digestion with XbaI and EcoRI, dephosphorylated with shrimp alkaline 
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phosphatase (Promega), and gel purified similar to the PCR product.  The digested vector 
and PCR product were ligated with T4 DNA Ligase using a rapid ligation method 
(LigaFast™ Rapid DNA Ligation System, Promega).  The product of the ligation 
reaction was used to transform chemically competent E. coli (One Shot® Top10 cells, 
Invitrogen).  After growth overnight on selective plates containing 30 µg/mL kanamycin, 
isolated colonies were picked and cultured in Luria broth with 30 µg/mL kanamycin.  
Plasmid DNA was purified as above from each of these subcultures and screened by 
restriction digestion using SmaI and AgeI.  We also screened for the presence of the insert 
by PCR using primers designed to amplify across the GFP:PrP fusion.  A candidate clone 
from the screening was subsequently sent to the Oklahoma State University Recombinant 
DNA/Protein Rescource Facility for DNA sequencing for confirmation of appropriate 
insertion in frame with GFP.  This plasmid was designated pEGFP:PrP. 
pEGFP:PrP was further modified to insert the signal peptide of elk PrP at the 
amino terminus of GFP.  The coding sequence of the elk signal peptide was PCR 
amplified using primers containing restriction sites NheI (sense primer) and AgeI (anti-
sense primer).  Both vector pEGFP:PrP and the PCR amplicon were digested with AgeI
for one hour at 37°C and purified using a silica-based gel system (Wizard® SV Gel and 
PCR Clean-Up System, Promega) which removed AgeI and allowed us to change the 
reaction buffer.  Each AgeI digested product was then subjected to digestion with NheI
for 16 hours at 37°C and purified as above.  These products were ligated as above, the 
product of the ligation reaction used to transform E. coli, and transformants selected on 
kanamycin plates.  Isolated colonies were screened for the presence of insert by PCR as 
above and restriction digestion with HaeII for 1 hour at 37° C and confirmed by DNA 
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sequencing.  This plasmid was designated pSig:EGFP:PrP.  Each plasmid (pEGFP, 
pEGFP:PrP, and pSig:EGFP:PrP) was grown in cultures (100 mL) of selective media and 
purified using procedures for isolation of endotoxin free, highly pure preparations of 
plasmid DNA (EndoFree Plasmid Maxi, Qiagen). 
 
Transfection of BL3.1 cells with pEGFP, pEGFP:PrP, and pSig:EGFP:PrP 
Optimization of transfection with three different plasmids was performed in 12-
well cell culture plates (Corning) in a volume of 500µL by using a range of cell 
concentrations (4 x 105 – 3 x 106 cells/well), a range of liposome transfection reagent 
(DMRIE-C, Invitrogen) volumes (0-6 µL/well), and a range of plasmid DNA (0.5-8 
µg/well).  After 5 hours, the media was replaced and the cells incubated a further 24 
hours.  The cells were then collected by centrifugation at 800g X 10 minutes (for each 
collection step), washed with Dulbecco’s phosphate buffered saline (DPBS, Invitrogen, 
pH 7.4) and resuspended in DPBS for evaluation of expression.  Transient expression 
was evaluated by flow cytometery using a Becton Dickinson  FACSCcalibur instrument 
with Ar laser 488 nm excitation and 530±15 nm band  pass filter for GFP fluorescence.   
After flow cytometry, the cells were fixed in 4% paraformaldehyde/DPBS (pH 
7.4) at room temperature for thirty minutes, followed by two washes in DPBS of ten 
minutes each.  The fixed cells were then applied to microscope slides and overlaid with a 
coverslip.  The coverslip was sealed using rubber cement.  Localization of fluorescence 
in the cell was performed on fixed cells by confocal microscopy using a Leica SP-2 
instrument with Ar laser 488 nm excitation and adjustable spectral filter for GFP 
fluorescence. 
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G418 Sensitivity of BL3.1 cells 
In anticipation of selecting clones with stable expression of the fusion protein, we 
tested the ability of these cells to grow in the presence of G418 (Geneticin®, Invitrogen), 
an aminoglycoside antibiotic related to gentamicin.  Cells were grown in 6 well plates 
with concentrations of G418 ranging from 0 to 1000 ug/mL in growth media for up to 




EGFP:PrP expression vector construction 
Diagrams of vectors highlighting construction steps are shown at figure 4-1 and a 
diagram showing the predicted fusion protein is shown at figure 4-2.  Note that there are 
two linker sequences, one between each fusion.  The first linker sequence (located 
between the signal peptide and EGFP) contains the amino acid sequence is Arg-Pro-Val-
Ala.  The other linker lies between EGFP and PrP and reads Asn-Ser-Glu.  Screening for 
the presence of inserts into vectors was performed by both PCR and restriction digest 
analysis.  An example of the final screening step for pSig:EGFP:PrP is shown at figure 4-
3 and represents two possible candidates out of a total of over 60 plasmids screened.  
Both of these plasmids contained the signal peptide inserted in frame with EGFP:PrP as 
demonstrated by sequence analysis. 
 
Transfection of BL3.1 cells with pEGFP, pEGFP:PrP, and pSig:EGFP:PrP 
We tested multiple variations of parameters for transfection of BL3.1 cells, 
changing the amounts of liposomal transfection reagent, plasmid DNA, and cell 
concentration.  The results of an example of these transfection experiments as measured 
by percent of fluorescent cells detected using flow cytometry are shown at figure 4-4.  
Transfection with pEGFP consistently resulted in 25-30% fluorescent cells, whereas 
transfection with pEGFP:PrP resulted in less than 5% fluorescent cells.  We were unable 
to demonstrate fluorescence using pSig:EGFP:PrP in spite of multiple attempts using a 
variety of transfection parameters.  The dramatic decrease in efficiency using pEGFP:PrP 
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as compared to EGFP was not surprising since we expected the lack of signal peptide 
would lead to cytosolic expression of the fusion protein which contained a highly 
hydrophobic GPI anchor signal sequence which would probably prevent proper folding 
of the protein.  However, the lack of expression of pSig:EGFP:PrP was surprising 
because we expected the signal peptide to direct the translocation of the fusion protein 
into the endoplasmic reticulum where a GPI anchor would be added to replace the GPI 
anchor signal sequence. 
We next attempted to localize the fluorescence inside the cell by confocal 
microscopy.  As expected, transfection with pEGFPC1 alone resulted in a dispersed 
pattern of fluorescence (figure 4-5), compatible with expression of soluble green 
fluorescent protein as shown by other investigators [292].  The high transfection 
efficiency as shown by flow cytometry and the demonstration of fluorescence in 
transfected cells confirm that the selected expression vector and transfection strategy are 
compatible with BL3.1 cells. 
Confocal microscopy of cells transfected with pEFGP:PrP demonstrated a nuclear 
or perinuclear pattern of fluorescence (figure 4-6), suggesting that the lack of signal 
peptide on this fusion protein resulted in accumulation in or near the nucleus, nuclear 
membrane, or endoplasmic reticulum.  Since EGFP is a soluble protein and since there is 
no signal peptide to direct binding to the signal recognition particle (SRP) of the 
endoplasmic reticulum, one would predict that free ribosomes would initiate translation 
of this fusion protein in the cytosol.  The accumulation of the fusion protein in a nuclear 
or perinuclear pattern could be explained by a variety of mechanisms.   
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The most likely explanation for the accumulation of nuclear or perinuclear 
fluorescence in cells transfected with pEGFP:PrP is that overexpression of the fusion 
protein resulted in accumulation of misfolded proteins that were quickly ubiquitinated 
and directed to the proteosome for degradation.  The presence of a translated, highly 
hydrophobic GPI signal sequence might contribute to transient localization of the fusion 
protein to a nuclear or endoplasmic reticulum membrane.  
Another possible explanation is the formation of perinuclear PrP aggregates 
similar to that shown by Kristiansen et al. as demonstrated by immunofluorescent 
staining of cells overexpressing PrPC [293].  These aggregates were associated with the 
cytosolic chaperone Hsc70 as demonstrated by co-immunofluorescent staining.  Other 
authors have described similar findings [138, 294, 295], but these studies involved PrPC
retrotranslocated from the endoplasmic reticulum as evidenced by the presence of a GPI 
anchor at the C terminus or a truncated PrP lacking the N terminal signal peptide and the 
C terminal GPI anchor signal sequence (23-230 PrP).  The expression product of 
pEGFP:PrP probably has a GPI signal sequence, not a GPI anchor because the fusion 
protein lacks a signal peptide for direction into the endoplasmic reticulum where the 
addition of the GPI anchor takes place.  Therefore, the pattern accumulation of 
fluorescence in these cells may be due to factors other than those demonstrated by the 
above studies. 
An alternative explanation for the pattern of fluorescence in BL3.1 cells 
transfected with pEGFP:PrP is the trafficking of the PrP component to the nucleus.  In 
experiments using C-terminally truncated PrP fused to the N-terminus of GFP, Gu et al. 
demonstrated that there are two cryptic nuclear localization signals (NLS) in the mature 
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PrP at residues 23-28 and 101-106 (human codons) that act synergistically to localize the 
fusion protein to the nucleus [296].  Whether these NLSs are functional in the context of 
PrP fused to the C-terminus of GFP are unknown, but other investigators have shown that 
PrP can be directed to the nucleus independent of NLSs.  In a study using inducible 
neuronal cell lines expressing 23-230 PrP (a truncated version of PrP lacking the N-
terminal signal peptide and the GPI anchor), Crozet et al. found that 23-230 PrP localized 
primarily to the nucleus and was not toxic [297].  They ascribed this localization to an 
intrinsic DNA binding capacity of PrP because mutations of the NLS had no effect on 23-
230 PrP localization to the nucleus and 23-230 PrP had the same DNA binding capacity 
as PrPC and PrPSC. The presence of a translated GPI signal sequence in our construct 
could alter the transport or localization of EGFP:PrP to a perinuclear membrane due to 
the highly hydrophobic nature of this sequence. 
We were unable to demonstrate fluorescence in cells transfected with 
pSig:EGFP:PrP by confocal microscopy (figure 4-7) in spite of many attempts to do.  
GFP has been used by other investigators to identify trafficking and localization signals 
[298, 299], so it is unlikely that the GFP coding sequence interfered with translocation 
through the endoplasmic reticulum.  Since we were able to visualize fluorescence by 
transfecting cells with both EGFP and EGFP:PrP, the most likely reason we saw no 
fluorescence in Sig:EGFP:PrP transfected cells involves the signal peptide and/or it’s 
relation to EGFP:PrP. 
Secretory and membrane proteins all possess an N terminal signal peptide that is 
responsible for direction of the ribosome to the endoplasmic reticulum translocation 
channel and subsequent co-translational translocation of the protein into the endoplasmic 
160
reticulum [300].  Although there is no conserved canonical sequence, signal peptides of 
both prokaryotes and eukaryotes have a common structure comprised of a short, 
positively charged amino-terminal region, a central hydrophobic region, and a polar 
carboxy terminal region containing the cleavage site [301].  Signal peptides are 
responsible for co-translational translocation of their associated proteins through the 
endoplasmic reticulum.  The lack of consensus sequences for signal peptides and reports 
of different translocation efficiencies for different signal peptides [33, 302] suggests that 
there may be different regulatory factors dependent upon signal peptide sequences that 
control translocation.  Kang et al. have recently provided evidence that the signal peptide 
of PrP is one such regulated signal and that a pre-emptive quality control (pQC) 
mechanism prevents accumulation of misfolded PrP in the endoplasmic reticulum during 
periods of endoplasmic reticulum stress [303] by blocking translocation.   
Several studies have shown that mutations within and immediately after the signal 
peptide can have profound effects on the translocation of a protein across lipid bilayer 
membranes.  Geller et al. showed that insertion of two arginines immediately following 
the signal peptidase cleavage site in OmpA blocked its translocation in a cell free 
translocation system [304].  The insertion of a proline immediately following the signal 
peptidase cleavage site is inihibitory for translocation [305], and the substitution of a 
single arginine within the signal peptide of the pancreatic secretory trypsin inhibitor 
(SPINK1) results in rapid cytosolic degradation and abolishment of secretion of SPINK1 
[306].  The linker peptide between the signal peptide and GFP in the predicted fusion 
protein encoded by pSig:EGFP:PrP reads arginine-proline-valine-alanine-threonine.  The 
presence of this peptide could affect the presentation of the cleavage site to the signal 
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peptidase on the inner surface of the endoplasmic reticulum due to the presence of a 
positively charged arginine in close proximity to the hydrophobic region of the signal 
peptidase.  Thus the insertion of the linker peptide into our expression construct could 
account for the lack of expression in BL3.1 cells by profoundly altering the translocation 
of the fusion protein into the endoplasmic reticulum, leading to rapid direction to and 
degradation by the proteasome. 
The insertion of the linker peptide RPVAT (figure 4-2) between the signal peptide 
and GFP was an unintentional consequence of the methodology used to create the final 
epression vector, but the identification of a possible interruption of signal peptide 
function may prove to be an important insight in further characterization of PrP 
trafficking.  While the underlying toxic principle in prion diseases remains unknown, the 
highest suspicion lies with a gain of toxic function of the misfolded, aggregated form of 
PrP [307].  Prnp-/- knockout mice are essentially phenotypically normal and completely 
resistant challenge with prion agents, indicating that a loss of normal function of PrP is 
less likely to be responsible for the pathology associated with prion diseases.  The exact 
intracellular location where a toxic, misfolded PrP might act is yet to be elucidated.  
Several studies have associated misfolded, aggregated PrP at different (and sometimes 
conflicting) cellular compartments, including the cytoplasm [138, 308-310], the 
membrane of the endoplasmic reticulum [33, 139, 311, 312], and the lumen of the 
endoplasmic reticulum [303].  The identification of a possible inhibitory amino acid or 
peptide sequence for the signal peptide of PrP could provide a tool for further 
investigation of subcellular localization of toxic PrP. 
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G418 Sensitivity of BL3.1 cells 
We found that BL3.1 cells were greater than 99% sensitive to G418 at a 
concentration of 750 µg/mL and above (figure 4-8).  The plasmids used in this study 
carry a neomycin resistance gene that confers resistance to G418.  We anticipated 
selection of stable transformants after demonstrating proof of concept using transient 
expression of pSig:EGFP:PrP, but in the absence of expression of the fusion protein at 





In this study, we have demonstrated that BL3.1 cells are amenable to transfection 
and transient expression of EGFP and, to a lesser extent, EGFP:PrP using a liposomal 
transfection strategy.  Expression of EGFP:PrP resulted in a nuclear or perinuclear 
pattern of fluorescence consistent with the abnormal aggregation shown by other 
investigators using models to overexpress PrP in the cytosol.  We also found that 
transfection with pSig:EGFP:PrP resulted very little to no expression of the fusion 
protein.  The lack of expression of EGFP:PrP at the cell surface prevented us from 
pursuing planned experiments to demonstrate conversion of the fusion protein to an 
aggregated form consistent with PrPSC after exposure to exogenous PrPSC. The reason for 
this lack of expression is unknown, but a possible explanation is that there was a signal 
peptide inhibitory sequence included in the fusion protein coding sequence.  Further 
exploration and characterization of this possibility could result in insights into the precise 
trafficking of PrP through the secretory pathway with implications on the underlying 
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Figure 4-1.  Outline of steps in construction of expression vectors.  The coding sequence for cervid 
prion protein was inserted into pEGFPC1 between restriction sites EcoRI and XbaI 
resulting in pEGF:PPrP.  The signal peptide was then inserted between restriction sites 











Figure 4-2.  Diagram of predicted protein expressed from pSig:EGFP:PrP. 
184
Figure 4-3.  Screening of isolated colonies by restriction digest with HaeII.  Plasmids were purified 
from isolated colonies and digested with Hae II.  Successful ligation of signal peptide 
indicated by loss of HaeII site, as evidenced by two of clones screened (lane 8 on top, lane 
11 middle).  Lanes 14 in middle and 7 at bottom contain uncut plasmid DNA as controls.  
Marker lanes at each end are HyperLadder I, Bioline.  Insertion of signal peptide in 
frame with EGFP:PrP was confirmed by DNA sequence analysis. 
185





















Figure 4-4.  Optimized transfection of BL3.1 cells with each plasmid using 5µL DMRIE-C/well and a 
range of DNA concentration from 0-4 µg/well as measured by percent of fluorescent cells 
detected by flow cytometry using a Becton Dickinson  FACSCcalibur instrument with Ar 





Figure 4-5.  Combined serial sections of BL3.1 cells transfected with pEGFPC1.  A.  White light 
image B. Fluorescent image  C. Combined image.  Bar = 40 µm. 
 
A B C. B. C. 
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Figure 4-6.  Combined serial secions of BL3.1 cells transfected with pSig:EGFPC1.  A.  White light 




Figure 4-7.  Combined serial secions of BL3.1 cells transfected with pSig:EGFP:PrP  A.  White light 
image B. Fluorescent image  C. Combined image.  No fluorescence was noted in any 


























Figure 4-8.  Sensitivity of BL3.1 cells to increasing concentrations of G418 (Geneticin®, Invitrogen).  
Cells were grown in 6-well plates with increasing concentrations of G418 in growth 
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